ZA200701943B - Compositions and their uses for lysosomal enzyme deficiencies - Google Patents

Info

Publication number

ZA200701943B

ZA200701943B ZA200701943A ZA200701943A ZA200701943B ZA 200701943 B ZA200701943 B ZA 200701943B ZA 200701943 A ZA200701943 A ZA 200701943A ZA 200701943 A ZA200701943 A ZA 200701943A ZA 200701943 B ZA200701943 B ZA 200701943B

Authority

ZA

South Africa

Prior art keywords

protein

ygp

disease

payload

composition

Prior art date

2004-09-17

Links

• Espacenet
• Global Dossier
• Discuss

• 102000004190 Enzymes Human genes 0.000 title claims abstract description 50
• 108090000790 Enzymes Proteins 0.000 title claims abstract description 50
• 230000002132 lysosomal effect Effects 0.000 title claims abstract description 40
• 239000000203 mixture Substances 0.000 title claims description 260
• 230000007812 deficiency Effects 0.000 title claims description 36
• 238000000034 method Methods 0.000 claims abstract description 91
• 210000005253 yeast cell Anatomy 0.000 claims abstract description 88
• 230000002950 deficient Effects 0.000 claims abstract description 47
• FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims abstract description 34
• 229920002498 Beta-glucan Polymers 0.000 claims abstract description 34
• 239000002904 solvent Substances 0.000 claims abstract description 14
• 239000013589 supplement Substances 0.000 claims abstract description 12
• 210000004027 cell Anatomy 0.000 claims description 239
• 108090000623 proteins and genes Proteins 0.000 claims description 179
• 102000004169 proteins and genes Human genes 0.000 claims description 137
• 210000002540 macrophage Anatomy 0.000 claims description 115
• LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 claims description 60
• 229920002873 Polyethylenimine Polymers 0.000 claims description 56
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 56
• 108010017544 Glucosylceramidase Proteins 0.000 claims description 52
• 229920001661 Chitosan Polymers 0.000 claims description 49
• 229940088598 enzyme Drugs 0.000 claims description 49
• 238000011282 treatment Methods 0.000 claims description 41
• 235000010443 alginic acid Nutrition 0.000 claims description 40
• 229920000615 alginic acid Polymers 0.000 claims description 40
• 201000010099 disease Diseases 0.000 claims description 38
• 239000013604 expression vector Substances 0.000 claims description 36
• FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 35
• 229940072056 alginate Drugs 0.000 claims description 35
• 150000007523 nucleic acids Chemical class 0.000 claims description 29
• 108020004707 nucleic acids Proteins 0.000 claims description 29
• 102000039446 nucleic acids Human genes 0.000 claims description 29
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 29
• 239000008194 pharmaceutical composition Substances 0.000 claims description 27
• 208000015872 Gaucher disease Diseases 0.000 claims description 24
• 108700026244 Open Reading Frames Proteins 0.000 claims description 24
• 229920000057 Mannan Polymers 0.000 claims description 22
• 239000003814 drug Substances 0.000 claims description 21
• 230000002255 enzymatic effect Effects 0.000 claims description 20
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 20
• 229920000729 poly(L-lysine) polymer Polymers 0.000 claims description 19
• 229920001285 xanthan gum Polymers 0.000 claims description 19
• GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 claims description 18
• 208000015439 Lysosomal storage disease Diseases 0.000 claims description 18
• 208000035475 disorder Diseases 0.000 claims description 18
• 238000004519 manufacturing process Methods 0.000 claims description 18
• 230000015556 catabolic process Effects 0.000 claims description 17
• 208000008955 Mucolipidoses Diseases 0.000 claims description 16
• 238000006731 degradation reaction Methods 0.000 claims description 16
• 210000001539 phagocyte Anatomy 0.000 claims description 16
• 206010057249 Phagocytosis Diseases 0.000 claims description 15
• 230000008782 phagocytosis Effects 0.000 claims description 15
• 208000011580 syndromic disease Diseases 0.000 claims description 14
• 230000007547 defect Effects 0.000 claims description 13
• 230000032258 transport Effects 0.000 claims description 13
• 229920001184 polypeptide Polymers 0.000 claims description 12
• 108091034117 Oligonucleotide Proteins 0.000 claims description 11
• 108091006088 activator proteins Proteins 0.000 claims description 10
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 10
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 10
• 229920002101 Chitin Polymers 0.000 claims description 9
• 238000000338 in vitro Methods 0.000 claims description 9
• 206010028093 mucopolysaccharidosis Diseases 0.000 claims description 9
• 206010053185 Glycogen storage disease type II Diseases 0.000 claims description 8
• 108020004511 Recombinant DNA Proteins 0.000 claims description 8
• 239000012190 activator Substances 0.000 claims description 8
• 150000002632 lipids Chemical class 0.000 claims description 8
• 238000003860 storage Methods 0.000 claims description 8
• 102100022548 Beta-hexosaminidase subunit alpha Human genes 0.000 claims description 7
• 239000003248 enzyme activator Substances 0.000 claims description 7
• 230000004060 metabolic process Effects 0.000 claims description 7
• 206010056886 Mucopolysaccharidosis I Diseases 0.000 claims description 6
• 210000001986 peyer's patch Anatomy 0.000 claims description 6
• 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 5
• 208000024720 Fabry Disease Diseases 0.000 claims description 5
• 208000017462 Galactosialidosis Diseases 0.000 claims description 5
• 229920002683 Glycosaminoglycan Polymers 0.000 claims description 5
• 108010052285 Membrane Proteins Proteins 0.000 claims description 5
• 235000012000 cholesterol Nutrition 0.000 claims description 5
• 208000025919 mucopolysaccharidosis type 7 Diseases 0.000 claims description 5
• 239000002773 nucleotide Substances 0.000 claims description 5
• 125000003729 nucleotide group Chemical group 0.000 claims description 5
• 230000001502 supplementing effect Effects 0.000 claims description 5
• 208000029602 Alpha-N-acetylgalactosaminidase deficiency Diseases 0.000 claims description 4
• 206010068220 Aspartylglucosaminuria Diseases 0.000 claims description 4
• 208000011518 Danon disease Diseases 0.000 claims description 4
• 208000001948 Farber Lipogranulomatosis Diseases 0.000 claims description 4
• 208000033149 Farber disease Diseases 0.000 claims description 4
• 208000001905 GM2 Gangliosidoses Diseases 0.000 claims description 4
• 208000010055 Globoid Cell Leukodystrophy Diseases 0.000 claims description 4
• 208000001500 Glycogen Storage Disease Type IIb Diseases 0.000 claims description 4
• 208000035148 Glycogen storage disease due to LAMP-2 deficiency Diseases 0.000 claims description 4
• 208000032007 Glycogen storage disease due to acid maltase deficiency Diseases 0.000 claims description 4
• 208000015178 Hurler syndrome Diseases 0.000 claims description 4
• 208000028226 Krabbe disease Diseases 0.000 claims description 4
• 102100033448 Lysosomal alpha-glucosidase Human genes 0.000 claims description 4
• 201000010991 Marinesco-Sjogren syndrome Diseases 0.000 claims description 4
• 102000018697 Membrane Proteins Human genes 0.000 claims description 4
• 206010072927 Mucolipidosis type I Diseases 0.000 claims description 4
• 206010072928 Mucolipidosis type II Diseases 0.000 claims description 4
• 206010056893 Mucopolysaccharidosis VII Diseases 0.000 claims description 4
• 208000021811 Sandhoff disease Diseases 0.000 claims description 4
• 208000010112 Spinocerebellar Degenerations Diseases 0.000 claims description 4
• 208000022292 Tay-Sachs disease Diseases 0.000 claims description 4
• 108700001567 Type I Schindler Disease Proteins 0.000 claims description 4
• 208000026589 Wolman disease Diseases 0.000 claims description 4
• 210000004443 dendritic cell Anatomy 0.000 claims description 4
• 201000008049 fucosidosis Diseases 0.000 claims description 4
• 201000004502 glycogen storage disease II Diseases 0.000 claims description 4
• 201000008977 glycoproteinosis Diseases 0.000 claims description 4
• 208000011985 sialidosis Diseases 0.000 claims description 4
• 208000029448 Chylomicron retention disease Diseases 0.000 claims description 3
• 208000031879 Chédiak-Higashi syndrome Diseases 0.000 claims description 3
• 206010011777 Cystinosis Diseases 0.000 claims description 3
• 102000052510 DNA-Binding Proteins Human genes 0.000 claims description 3
• 101710096438 DNA-binding protein Proteins 0.000 claims description 3
• 201000008892 GM1 Gangliosidosis Diseases 0.000 claims description 3
• 201000008905 GM2 gangliosidosis Diseases 0.000 claims description 3
• 229920002527 Glycogen Polymers 0.000 claims description 3
• 102000003886 Glycoproteins Human genes 0.000 claims description 3
• 108090000288 Glycoproteins Proteins 0.000 claims description 3
• 208000006933 Hermanski-Pudlak Syndrome Diseases 0.000 claims description 3
• 206010071775 Hermansky-Pudlak syndrome Diseases 0.000 claims description 3
• 101001045440 Homo sapiens Beta-hexosaminidase subunit alpha Proteins 0.000 claims description 3
• 108700037017 Hyaluronidase Deficiency Proteins 0.000 claims description 3
• 208000005503 Hyaluronidase deficiency Diseases 0.000 claims description 3
• 208000027933 Mannosidase Deficiency disease Diseases 0.000 claims description 3
• 208000025915 Mucopolysaccharidosis type 6 Diseases 0.000 claims description 3
• 208000010577 Niemann-Pick disease type C Diseases 0.000 claims description 3
• 101710172711 Structural protein Proteins 0.000 claims description 3
• 208000007930 Type C Niemann-Pick Disease Diseases 0.000 claims description 3
• 230000000692 anti-sense effect Effects 0.000 claims description 3
• SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims description 3
• 150000002148 esters Chemical class 0.000 claims description 3
• 210000003754 fetus Anatomy 0.000 claims description 3
• 208000029281 geleophysic dysplasia Diseases 0.000 claims description 3
• 150000004676 glycans Chemical class 0.000 claims description 3
• 229940096919 glycogen Drugs 0.000 claims description 3
• 210000001865 kupffer cell Anatomy 0.000 claims description 3
• 210000001821 langerhans cell Anatomy 0.000 claims description 3
• 230000002025 microglial effect Effects 0.000 claims description 3
• 210000001616 monocyte Anatomy 0.000 claims description 3
• 208000011045 mucopolysaccharidosis type 3 Diseases 0.000 claims description 3
• 210000000440 neutrophil Anatomy 0.000 claims description 3
• 201000010108 pycnodysostosis Diseases 0.000 claims description 3
• SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims description 3
• 108091006024 signal transducing proteins Proteins 0.000 claims description 3
• 102000034285 signal transducing proteins Human genes 0.000 claims description 3
• 150000003408 sphingolipids Chemical class 0.000 claims description 3
• 208000035374 Chronic visceral acid sphingomyelinase deficiency Diseases 0.000 claims description 2
• 208000037326 Gaucher disease type 1 Diseases 0.000 claims description 2
• 208000037310 Gaucher disease type 2 Diseases 0.000 claims description 2
• 208000037311 Gaucher disease type 3 Diseases 0.000 claims description 2
• 208000035343 Infantile neurovisceral acid sphingomyelinase deficiency Diseases 0.000 claims description 2
• 206010072929 Mucolipidosis type III Diseases 0.000 claims description 2
• 206010028095 Mucopolysaccharidosis IV Diseases 0.000 claims description 2
• 201000000794 Niemann-Pick disease type A Diseases 0.000 claims description 2
• 201000000791 Niemann-Pick disease type B Diseases 0.000 claims description 2
• 102000005262 Sulfatase Human genes 0.000 claims description 2
• 208000007824 Type A Niemann-Pick Disease Diseases 0.000 claims description 2
• 208000008291 Type B Niemann-Pick Disease Diseases 0.000 claims description 2
• 210000004381 amniotic fluid Anatomy 0.000 claims description 2
• 208000024042 cholesterol ester storage disease Diseases 0.000 claims description 2
• 208000013760 cholesteryl ester storage disease Diseases 0.000 claims description 2
• 210000003979 eosinophil Anatomy 0.000 claims description 2
• 210000003714 granulocyte Anatomy 0.000 claims description 2
• 230000010189 intracellular transport Effects 0.000 claims description 2
• 208000036546 leukodystrophy Diseases 0.000 claims description 2
• 235000013336 milk Nutrition 0.000 claims description 2
• 239000008267 milk Substances 0.000 claims description 2
• 210000004080 milk Anatomy 0.000 claims description 2
• 208000010978 mucopolysaccharidosis type 4 Diseases 0.000 claims description 2
• 210000003024 peritoneal macrophage Anatomy 0.000 claims description 2
• 108060007951 sulfatase Proteins 0.000 claims description 2
• 210000004291 uterus Anatomy 0.000 claims description 2
• 102000004547 Glucosylceramidase Human genes 0.000 claims 2
• 108020004459 Small interfering RNA Proteins 0.000 claims 2
• 102100027096 Nucleotide exchange factor SIL1 Human genes 0.000 claims 1
• 230000003458 metachromatic effect Effects 0.000 claims 1
• 230000001225 therapeutic effect Effects 0.000 abstract description 13
• 239000002245 particle Substances 0.000 description 295
• 108020004414 DNA Proteins 0.000 description 118
• 235000018102 proteins Nutrition 0.000 description 111
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 85
• 238000009472 formulation Methods 0.000 description 69
• 229920000642 polymer Polymers 0.000 description 48
• 241000699670 Mus sp. Species 0.000 description 47
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 44
• 102100033342 Lysosomal acid glucosylceramidase Human genes 0.000 description 43
• 125000002091 cationic group Chemical group 0.000 description 43
• 238000001727 in vivo Methods 0.000 description 43
• 210000001845 splenic macrophage Anatomy 0.000 description 42
• 239000013612 plasmid Substances 0.000 description 37
• 239000000243 solution Substances 0.000 description 37
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 36
• 239000002953 phosphate buffered saline Substances 0.000 description 36
• 239000000725 suspension Substances 0.000 description 36
• 241000699666 Mus <mouse, genus> Species 0.000 description 35
• 239000000427 antigen Substances 0.000 description 32
• -1 vinyl pyrollidone Chemical compound 0.000 description 32
• 108091007433 antigens Proteins 0.000 description 31
• 102000036639 antigens Human genes 0.000 description 31
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 30
• 235000019441 ethanol Nutrition 0.000 description 30
• 241001529936 Murinae Species 0.000 description 29
• 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 29
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 27
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
• 239000008188 pellet Substances 0.000 description 27
• 239000003826 tablet Substances 0.000 description 27
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 25
• 229920001503 Glucan Polymers 0.000 description 25
• 239000000463 material Substances 0.000 description 24
• 239000004098 Tetracycline Substances 0.000 description 23
• 230000000694 effects Effects 0.000 description 23
• 238000002360 preparation method Methods 0.000 description 23
• 235000019364 tetracycline Nutrition 0.000 description 23
• 150000003522 tetracyclines Chemical class 0.000 description 23
• 238000011534 incubation Methods 0.000 description 22
• 230000035772 mutation Effects 0.000 description 22
• 229960002180 tetracycline Drugs 0.000 description 22
• 229930101283 tetracycline Natural products 0.000 description 22
• 108010043121 Green Fluorescent Proteins Proteins 0.000 description 21
• 102000004144 Green Fluorescent Proteins Human genes 0.000 description 21
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 21
• 238000005119 centrifugation Methods 0.000 description 21
• 239000005090 green fluorescent protein Substances 0.000 description 21
• 241001465754 Metazoa Species 0.000 description 19
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 19
• 150000001875 compounds Chemical class 0.000 description 19
• 239000000843 powder Substances 0.000 description 19
• 239000004480 active ingredient Substances 0.000 description 18
• 238000011068 loading method Methods 0.000 description 18
• 239000002775 capsule Substances 0.000 description 16
• 102000005962 receptors Human genes 0.000 description 16
• 108020003175 receptors Proteins 0.000 description 16
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
• 239000000872 buffer Substances 0.000 description 15
• 230000006870 function Effects 0.000 description 15
• 210000001519 tissue Anatomy 0.000 description 15
• 108010048367 enhanced green fluorescent protein Proteins 0.000 description 14
• 239000000047 product Substances 0.000 description 14
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 13
• 206010028980 Neoplasm Diseases 0.000 description 13
• 238000010521 absorption reaction Methods 0.000 description 13
• 239000003795 chemical substances by application Substances 0.000 description 13
• 238000000799 fluorescence microscopy Methods 0.000 description 13
• 230000003463 hyperproliferative effect Effects 0.000 description 13
• 239000007788 liquid Substances 0.000 description 13
• 239000000126 substance Substances 0.000 description 13
• 229960005486 vaccine Drugs 0.000 description 13
• 102100040840 C-type lectin domain family 7 member A Human genes 0.000 description 12
• 108091008874 T cell receptors Proteins 0.000 description 12
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 12
• 230000001464 adherent effect Effects 0.000 description 12
• 201000011510 cancer Diseases 0.000 description 12
• 210000000952 spleen Anatomy 0.000 description 12
• 238000010254 subcutaneous injection Methods 0.000 description 12
• 239000007929 subcutaneous injection Substances 0.000 description 12
• 208000026350 Inborn Genetic disease Diseases 0.000 description 11
• 230000027455 binding Effects 0.000 description 11
• 239000003599 detergent Substances 0.000 description 11
• 238000010586 diagram Methods 0.000 description 11
• 208000016361 genetic disease Diseases 0.000 description 11
• 239000004615 ingredient Substances 0.000 description 11
• 230000003834 intracellular effect Effects 0.000 description 11
• 239000006228 supernatant Substances 0.000 description 11
• 235000014633 carbohydrates Nutrition 0.000 description 10
• 239000006285 cell suspension Substances 0.000 description 10
• 238000009826 distribution Methods 0.000 description 10
• 230000002068 genetic effect Effects 0.000 description 10
• 238000002347 injection Methods 0.000 description 10
• 239000007924 injection Substances 0.000 description 10
• 208000023275 Autoimmune disease Diseases 0.000 description 9
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
• 210000001744 T-lymphocyte Anatomy 0.000 description 9
• 235000001014 amino acid Nutrition 0.000 description 9
• 108010059297 beta-glucan receptor Proteins 0.000 description 9
• 210000004556 brain Anatomy 0.000 description 9
• 150000001720 carbohydrates Chemical class 0.000 description 9
• 229920006317 cationic polymer Polymers 0.000 description 9
• MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 9
• 230000028993 immune response Effects 0.000 description 9
• 230000001404 mediated effect Effects 0.000 description 9
• 230000000717 retained effect Effects 0.000 description 9
• 239000013598 vector Substances 0.000 description 9
• 229920000936 Agarose Polymers 0.000 description 8
• VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 8
• 108010031099 Mannose Receptor Proteins 0.000 description 8
• 238000004458 analytical method Methods 0.000 description 8
• 238000005516 engineering process Methods 0.000 description 8
• 239000012894 fetal calf serum Substances 0.000 description 8
• 238000001943 fluorescence-activated cell sorting Methods 0.000 description 8
• 239000012634 fragment Substances 0.000 description 8
• 125000005647 linker group Chemical group 0.000 description 8
• 238000010172 mouse model Methods 0.000 description 8
• 238000003305 oral gavage Methods 0.000 description 8
• 150000003839 salts Chemical class 0.000 description 8
• 239000011780 sodium chloride Substances 0.000 description 8
• 238000010186 staining Methods 0.000 description 8
• 238000001890 transfection Methods 0.000 description 8
• 241000972773 Aulopiformes Species 0.000 description 7
• 241000283707 Capra Species 0.000 description 7
• WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 7
• 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 7
• 206010036186 Porphyria non-acute Diseases 0.000 description 7
• 239000008367 deionised water Substances 0.000 description 7
• 229910021641 deionized water Inorganic materials 0.000 description 7
• 239000003085 diluting agent Substances 0.000 description 7
• 239000001963 growth medium Substances 0.000 description 7
• 210000003563 lymphoid tissue Anatomy 0.000 description 7
• 239000002609 medium Substances 0.000 description 7
• 238000007911 parenteral administration Methods 0.000 description 7
• 244000052769 pathogen Species 0.000 description 7
• 230000001717 pathogenic effect Effects 0.000 description 7
• 229920002401 polyacrylamide Polymers 0.000 description 7
• 229920000867 polyelectrolyte Polymers 0.000 description 7
• 239000003755 preservative agent Substances 0.000 description 7
• 235000019515 salmon Nutrition 0.000 description 7
• 210000000813 small intestine Anatomy 0.000 description 7
• 239000007787 solid Substances 0.000 description 7
• 239000011550 stock solution Substances 0.000 description 7
• 238000005406 washing Methods 0.000 description 7
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
• 229920002307 Dextran Polymers 0.000 description 6
• 108010069091 Dystrophin Proteins 0.000 description 6
• 108010010803 Gelatin Proteins 0.000 description 6
• 208000002678 Mucopolysaccharidoses Diseases 0.000 description 6
• 241000283973 Oryctolagus cuniculus Species 0.000 description 6
• 206010036182 Porphyria acute Diseases 0.000 description 6
• CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
• 241000700605 Viruses Species 0.000 description 6
• 125000000129 anionic group Chemical group 0.000 description 6
• 210000000988 bone and bone Anatomy 0.000 description 6
• 210000002421 cell wall Anatomy 0.000 description 6
• 210000000805 cytoplasm Anatomy 0.000 description 6
• 238000010790 dilution Methods 0.000 description 6
• 239000012895 dilution Substances 0.000 description 6
• 239000002270 dispersing agent Substances 0.000 description 6
• 108010083421 fluorescein isothiocyanate-concanavalin A Proteins 0.000 description 6
• 239000011888 foil Substances 0.000 description 6
• 210000001035 gastrointestinal tract Anatomy 0.000 description 6
• 229920000159 gelatin Polymers 0.000 description 6
• 239000008273 gelatin Substances 0.000 description 6
• 235000019322 gelatine Nutrition 0.000 description 6
• 235000011852 gelatine desserts Nutrition 0.000 description 6
• 210000004408 hybridoma Anatomy 0.000 description 6
• 230000001965 increasing effect Effects 0.000 description 6
• 210000004185 liver Anatomy 0.000 description 6
• 239000011859 microparticle Substances 0.000 description 6
• 239000002244 precipitate Substances 0.000 description 6
• 239000003380 propellant Substances 0.000 description 6
• 230000001681 protective effect Effects 0.000 description 6
• 238000002255 vaccination Methods 0.000 description 6
• 108700028369 Alleles Proteins 0.000 description 5
• BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 5
• 102000001039 Dystrophin Human genes 0.000 description 5
• 108010051696 Growth Hormone Proteins 0.000 description 5
• 208000031226 Hyperlipidaemia Diseases 0.000 description 5
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
• 241000124008 Mammalia Species 0.000 description 5
• 229920001213 Polysorbate 20 Polymers 0.000 description 5
• 201000010273 Porphyria Cutanea Tarda Diseases 0.000 description 5
• 102100038803 Somatotropin Human genes 0.000 description 5
• 238000002835 absorbance Methods 0.000 description 5
• 125000003275 alpha amino acid group Chemical group 0.000 description 5
• 150000001413 amino acids Chemical class 0.000 description 5
• 238000013459 approach Methods 0.000 description 5
• 230000008901 benefit Effects 0.000 description 5
• 210000001185 bone marrow Anatomy 0.000 description 5
• 239000002552 dosage form Substances 0.000 description 5
• 229940079593 drug Drugs 0.000 description 5
• 239000003937 drug carrier Substances 0.000 description 5
• 239000000975 dye Substances 0.000 description 5
• 238000000605 extraction Methods 0.000 description 5
• 239000000122 growth hormone Substances 0.000 description 5
• 230000003053 immunization Effects 0.000 description 5
• 239000002198 insoluble material Substances 0.000 description 5
• 230000000968 intestinal effect Effects 0.000 description 5
• 238000007912 intraperitoneal administration Methods 0.000 description 5
• 230000002147 killing effect Effects 0.000 description 5
• 230000014759 maintenance of location Effects 0.000 description 5
• 239000004005 microsphere Substances 0.000 description 5
• 201000006417 multiple sclerosis Diseases 0.000 description 5
• 229920003023 plastic Polymers 0.000 description 5
• 229920001223 polyethylene glycol Polymers 0.000 description 5
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 5
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 5
• 229920001282 polysaccharide Polymers 0.000 description 5
• 239000005017 polysaccharide Substances 0.000 description 5
• 150000004804 polysaccharides Chemical class 0.000 description 5
• 230000002685 pulmonary effect Effects 0.000 description 5
• 239000002002 slurry Substances 0.000 description 5
• 238000007920 subcutaneous administration Methods 0.000 description 5
• 239000000758 substrate Substances 0.000 description 5
• 235000000346 sugar Nutrition 0.000 description 5
• 230000009885 systemic effect Effects 0.000 description 5
• 239000003053 toxin Substances 0.000 description 5
• 231100000765 toxin Toxicity 0.000 description 5
• 108700012359 toxins Proteins 0.000 description 5
• 239000003981 vehicle Substances 0.000 description 5
• PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
• VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
• 241000606748 Actinobacillus pleuropneumoniae Species 0.000 description 4
• 238000011740 C57BL/6 mouse Methods 0.000 description 4
• BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 4
• 241000792859 Enema Species 0.000 description 4
• 241000588724 Escherichia coli Species 0.000 description 4
• 102100024023 Histone PARylation factor 1 Human genes 0.000 description 4
• 101001047783 Homo sapiens Histone PARylation factor 1 Proteins 0.000 description 4
• 101000956004 Homo sapiens Vitamin D-binding protein Proteins 0.000 description 4
• 208000000563 Hyperlipoproteinemia Type II Diseases 0.000 description 4
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 4
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 4
• 102000012745 Immunoglobulin Subunits Human genes 0.000 description 4
• 108010079585 Immunoglobulin Subunits Proteins 0.000 description 4
• 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 4
• 208000030162 Maple syrup disease Diseases 0.000 description 4
• KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 4
• 102100029268 Neurotrophin-3 Human genes 0.000 description 4
• 108090000099 Neurotrophin-4 Proteins 0.000 description 4
• 108091028043 Nucleic acid sequence Proteins 0.000 description 4
• 208000008589 Obesity Diseases 0.000 description 4
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
• 229930006000 Sucrose Natural products 0.000 description 4
• 230000005856 abnormality Effects 0.000 description 4
• 229920001448 anionic polyelectrolyte Polymers 0.000 description 4
• 239000003242 anti bacterial agent Substances 0.000 description 4
• 239000011230 binding agent Substances 0.000 description 4
• 229910000019 calcium carbonate Inorganic materials 0.000 description 4
• 239000000969 carrier Substances 0.000 description 4
• 238000006243 chemical reaction Methods 0.000 description 4
• 210000000349 chromosome Anatomy 0.000 description 4
• 238000000576 coating method Methods 0.000 description 4
• OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 4
• 238000013270 controlled release Methods 0.000 description 4
• 229920001577 copolymer Polymers 0.000 description 4
• 238000011161 development Methods 0.000 description 4
• 230000018109 developmental process Effects 0.000 description 4
• 235000014113 dietary fatty acids Nutrition 0.000 description 4
• 239000000839 emulsion Substances 0.000 description 4
• 210000001163 endosome Anatomy 0.000 description 4
• 239000007920 enema Substances 0.000 description 4
• 229940095399 enema Drugs 0.000 description 4
• 238000002641 enzyme replacement therapy Methods 0.000 description 4
• 229930195729 fatty acid Natural products 0.000 description 4
• 239000000194 fatty acid Substances 0.000 description 4
• 210000003608 fece Anatomy 0.000 description 4
• 238000001415 gene therapy Methods 0.000 description 4
• 239000011521 glass Substances 0.000 description 4
• 210000004837 gut-associated lymphoid tissue Anatomy 0.000 description 4
• 102000051433 human GC Human genes 0.000 description 4
• 238000003365 immunocytochemistry Methods 0.000 description 4
• 230000002163 immunogen Effects 0.000 description 4
• 230000001976 improved effect Effects 0.000 description 4
• 239000002502 liposome Substances 0.000 description 4
• 239000000314 lubricant Substances 0.000 description 4
• 210000004072 lung Anatomy 0.000 description 4
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
• 208000024393 maple syrup urine disease Diseases 0.000 description 4
• 238000007431 microscopic evaluation Methods 0.000 description 4
• 235000020824 obesity Nutrition 0.000 description 4
• 239000003921 oil Substances 0.000 description 4
• 235000019198 oils Nutrition 0.000 description 4
• 210000000056 organ Anatomy 0.000 description 4
• 230000036961 partial effect Effects 0.000 description 4
• 239000000825 pharmaceutical preparation Substances 0.000 description 4
• 229940127557 pharmaceutical product Drugs 0.000 description 4
• 239000008363 phosphate buffer Substances 0.000 description 4
• 239000004033 plastic Substances 0.000 description 4
• 230000002829 reductive effect Effects 0.000 description 4
• 206010039073 rheumatoid arthritis Diseases 0.000 description 4
• 150000003384 small molecules Chemical class 0.000 description 4
• ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 4
• 210000004989 spleen cell Anatomy 0.000 description 4
• 238000006467 substitution reaction Methods 0.000 description 4
• 239000005720 sucrose Substances 0.000 description 4
• 150000008163 sugars Chemical class 0.000 description 4
• 239000004094 surface-active agent Substances 0.000 description 4
• 239000000375 suspending agent Substances 0.000 description 4
• 238000013268 sustained release Methods 0.000 description 4
• 239000012730 sustained-release form Substances 0.000 description 4
• 230000008685 targeting Effects 0.000 description 4
• 230000009261 transgenic effect Effects 0.000 description 4
• 238000011830 transgenic mouse model Methods 0.000 description 4
• 201000011296 tyrosinemia Diseases 0.000 description 4
• 239000000080 wetting agent Substances 0.000 description 4
• HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 3
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 3
• 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 3
• 102000055025 Adenosine deaminases Human genes 0.000 description 3
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
• 108020005544 Antisense RNA Proteins 0.000 description 3
• 206010003594 Ataxia telangiectasia Diseases 0.000 description 3
• 102100022641 Coagulation factor IX Human genes 0.000 description 3
• 201000003883 Cystic fibrosis Diseases 0.000 description 3
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
• 201000010374 Down Syndrome Diseases 0.000 description 3
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
• 108010054218 Factor VIII Proteins 0.000 description 3
• 102000001690 Factor VIII Human genes 0.000 description 3
• 201000007176 Factor XII Deficiency Diseases 0.000 description 3
• 208000027472 Galactosemias Diseases 0.000 description 3
• 208000001021 Hyperlipoproteinemia Type I Diseases 0.000 description 3
• 108090001090 Lectins Proteins 0.000 description 3
• 102000004856 Lectins Human genes 0.000 description 3
• 240000007472 Leucaena leucocephala Species 0.000 description 3
• 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
• 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 3
• 208000001826 Marfan syndrome Diseases 0.000 description 3
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
• 108010025020 Nerve Growth Factor Proteins 0.000 description 3
• 208000014060 Niemann-Pick disease Diseases 0.000 description 3
• 208000008425 Protein deficiency Diseases 0.000 description 3
• 206010039710 Scleroderma Diseases 0.000 description 3
• 108091081024 Start codon Proteins 0.000 description 3
• 208000001163 Tangier disease Diseases 0.000 description 3
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
• 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 3
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
• 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 3
• 201000006083 Xeroderma Pigmentosum Diseases 0.000 description 3
• 238000009825 accumulation Methods 0.000 description 3
• 239000002253 acid Substances 0.000 description 3
• 239000000783 alginic acid Substances 0.000 description 3
• 229960001126 alginic acid Drugs 0.000 description 3
• 150000004781 alginic acids Chemical class 0.000 description 3
• 229940088710 antibiotic agent Drugs 0.000 description 3
• 230000000890 antigenic effect Effects 0.000 description 3
• 239000007864 aqueous solution Substances 0.000 description 3
• 238000003556 assay Methods 0.000 description 3
• 210000003719 b-lymphocyte Anatomy 0.000 description 3
• WPIHMWBQRSAMDE-YCZTVTEBSA-N beta-D-galactosyl-(1->4)-beta-D-galactosyl-N-(pentacosanoyl)sphingosine Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO[C@@H]1O[C@H](CO)[C@H](O[C@@H]2O[C@H](CO)[C@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O)[C@H](O)\C=C\CCCCCCCCCCCCC WPIHMWBQRSAMDE-YCZTVTEBSA-N 0.000 description 3
• 229920002988 biodegradable polymer Polymers 0.000 description 3
• 239000004621 biodegradable polymer Substances 0.000 description 3
• 230000015572 biosynthetic process Effects 0.000 description 3
• 238000009835 boiling Methods 0.000 description 3
• 229940098773 bovine serum albumin Drugs 0.000 description 3
• 239000001506 calcium phosphate Substances 0.000 description 3
• OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical class [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 3
• 210000000170 cell membrane Anatomy 0.000 description 3
• 230000001413 cellular effect Effects 0.000 description 3
• 210000003169 central nervous system Anatomy 0.000 description 3
• 150000001840 cholesterol esters Chemical class 0.000 description 3
• 239000011248 coating agent Substances 0.000 description 3
• 230000000112 colonic effect Effects 0.000 description 3
• 239000003184 complementary RNA Substances 0.000 description 3
• 201000010251 cutis laxa Diseases 0.000 description 3
• 230000003111 delayed effect Effects 0.000 description 3
• 238000013461 design Methods 0.000 description 3
• 239000006185 dispersion Substances 0.000 description 3
• 239000012153 distilled water Substances 0.000 description 3
• 239000003995 emulsifying agent Substances 0.000 description 3
• 201000001386 familial hypercholesterolemia Diseases 0.000 description 3
• 150000004665 fatty acids Chemical class 0.000 description 3
• 230000002550 fecal effect Effects 0.000 description 3
• 239000000796 flavoring agent Substances 0.000 description 3
• GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical group O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 3
• 235000013305 food Nutrition 0.000 description 3
• 150000002305 glucosylceramides Chemical class 0.000 description 3
• 230000036541 health Effects 0.000 description 3
• BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 3
• 208000020346 hyperlipoproteinemia Diseases 0.000 description 3
• 210000000987 immune system Anatomy 0.000 description 3
• 239000003701 inert diluent Substances 0.000 description 3
• 238000001990 intravenous administration Methods 0.000 description 3
• 210000003734 kidney Anatomy 0.000 description 3
• 238000002372 labelling Methods 0.000 description 3
• 239000008101 lactose Substances 0.000 description 3
• 235000010445 lecithin Nutrition 0.000 description 3
• 239000000787 lecithin Substances 0.000 description 3
• 229940067606 lecithin Drugs 0.000 description 3
• 239000002523 lectin Substances 0.000 description 3
• 210000004698 lymphocyte Anatomy 0.000 description 3
• 239000003550 marker Substances 0.000 description 3
• 239000011159 matrix material Substances 0.000 description 3
• 108020004999 messenger RNA Proteins 0.000 description 3
• 230000000813 microbial effect Effects 0.000 description 3
• 244000005700 microbiome Species 0.000 description 3
• 238000000386 microscopy Methods 0.000 description 3
• 230000005012 migration Effects 0.000 description 3
• 238000013508 migration Methods 0.000 description 3
• 210000003470 mitochondria Anatomy 0.000 description 3
• 238000002156 mixing Methods 0.000 description 3
• 208000022018 mucopolysaccharidosis type 2 Diseases 0.000 description 3
• 210000004400 mucous membrane Anatomy 0.000 description 3
• 201000006938 muscular dystrophy Diseases 0.000 description 3
• 238000002703 mutagenesis Methods 0.000 description 3
• 231100000350 mutagenesis Toxicity 0.000 description 3
• 239000004006 olive oil Substances 0.000 description 3
• 235000008390 olive oil Nutrition 0.000 description 3
• 230000011164 ossification Effects 0.000 description 3
• 108010089193 pattern recognition receptors Proteins 0.000 description 3
• 238000002823 phage display Methods 0.000 description 3
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
• 230000002335 preservative effect Effects 0.000 description 3
• 230000008569 process Effects 0.000 description 3
• 229960004063 propylene glycol Drugs 0.000 description 3
• 230000009467 reduction Effects 0.000 description 3
• 239000013049 sediment Substances 0.000 description 3
• 208000002491 severe combined immunodeficiency Diseases 0.000 description 3
• 208000007056 sickle cell anemia Diseases 0.000 description 3
• 210000003491 skin Anatomy 0.000 description 3
• 229910000029 sodium carbonate Inorganic materials 0.000 description 3
• 239000007909 solid dosage form Substances 0.000 description 3
• 239000007921 spray Substances 0.000 description 3
• 238000010561 standard procedure Methods 0.000 description 3
• 230000009469 supplementation Effects 0.000 description 3
• 239000000829 suppository Substances 0.000 description 3
• 239000003765 sweetening agent Substances 0.000 description 3
• 208000024891 symptom Diseases 0.000 description 3
• 239000006188 syrup Substances 0.000 description 3
• 235000020357 syrup Nutrition 0.000 description 3
• 239000012096 transfection reagent Substances 0.000 description 3
• 235000015112 vegetable and seed oil Nutrition 0.000 description 3
• JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
• YCIHPQHVWDULOY-FMZCEJRJSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide;hydrochloride Chemical compound Cl.C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O YCIHPQHVWDULOY-FMZCEJRJSA-N 0.000 description 2
• VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
• LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 description 2
• IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
• 208000010543 22q11.2 deletion syndrome Diseases 0.000 description 2
• RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
• 208000005452 Acute intermittent porphyria Diseases 0.000 description 2
• 102100029457 Adenine phosphoribosyltransferase Human genes 0.000 description 2
• 108010024223 Adenine phosphoribosyltransferase Proteins 0.000 description 2
• 208000005676 Adrenogenital syndrome Diseases 0.000 description 2
• 229920001817 Agar Polymers 0.000 description 2
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
• 239000005995 Aluminium silicate Substances 0.000 description 2
• 208000024827 Alzheimer disease Diseases 0.000 description 2
• 102100040214 Apolipoprotein(a) Human genes 0.000 description 2
• 208000034318 Argininemia Diseases 0.000 description 2
• 206010058298 Argininosuccinate synthetase deficiency Diseases 0.000 description 2
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
• BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
• 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 2
• 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 2
• 241000193738 Bacillus anthracis Species 0.000 description 2
• 208000020925 Bipolar disease Diseases 0.000 description 2
• 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 2
• 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 2
• 206010006187 Breast cancer Diseases 0.000 description 2
• 208000026310 Breast neoplasm Diseases 0.000 description 2
• 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 2
• 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 2
• 108010009575 CD55 Antigens Proteins 0.000 description 2
• 241000589874 Campylobacter fetus Species 0.000 description 2
• 102000037115 Carbamoyl-phosphate synthase (ammonia) Human genes 0.000 description 2
• 108090000447 Carbamoyl-phosphate synthase (ammonia) Proteins 0.000 description 2
• 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
• 102100027943 Carnitine O-palmitoyltransferase 1, liver isoform Human genes 0.000 description 2
• 101710120614 Carnitine O-palmitoyltransferase 1, liver isoform Proteins 0.000 description 2
• 101710108984 Carnitine O-palmitoyltransferase 1, muscle isoform Proteins 0.000 description 2
• 206010053684 Cerebrohepatorenal syndrome Diseases 0.000 description 2
• 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 description 2
• 201000006867 Charcot-Marie-Tooth disease type 4 Diseases 0.000 description 2
• 201000011297 Citrullinemia Diseases 0.000 description 2
• 241000193155 Clostridium botulinum Species 0.000 description 2
• 241000193468 Clostridium perfringens Species 0.000 description 2
• 102100030563 Coagulation factor XI Human genes 0.000 description 2
• 208000010200 Cockayne syndrome Diseases 0.000 description 2
• 108091026890 Coding region Proteins 0.000 description 2
• 208000008448 Congenital adrenal hyperplasia Diseases 0.000 description 2
• 208000034958 Congenital erythropoietic porphyria Diseases 0.000 description 2
• 229920002261 Corn starch Polymers 0.000 description 2
• 208000011231 Crohn disease Diseases 0.000 description 2
• 206010011778 Cystinuria Diseases 0.000 description 2
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
• NBSCHQHZLSJFNQ-QTVWNMPRSA-N D-Mannose-6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@@H]1O NBSCHQHZLSJFNQ-QTVWNMPRSA-N 0.000 description 2
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
• 101710088194 Dehydrogenase Proteins 0.000 description 2
• ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
• 102100024108 Dystrophin Human genes 0.000 description 2
• 238000002965 ELISA Methods 0.000 description 2
• 241000710188 Encephalomyocarditis virus Species 0.000 description 2
• 206010014989 Epidermolysis bullosa Diseases 0.000 description 2
• 208000007209 Erythropoietic Porphyria Diseases 0.000 description 2
• 102000003951 Erythropoietin Human genes 0.000 description 2
• 108090000394 Erythropoietin Proteins 0.000 description 2
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
• 108010076282 Factor IX Proteins 0.000 description 2
• 108010074864 Factor XI Proteins 0.000 description 2
• 108010049003 Fibrinogen Proteins 0.000 description 2
• 102000008946 Fibrinogen Human genes 0.000 description 2
• 206010072104 Fructose intolerance Diseases 0.000 description 2
• 108700028980 Fructosuria Proteins 0.000 description 2
• 208000009796 Gangliosidoses Diseases 0.000 description 2
• 241000206672 Gelidium Species 0.000 description 2
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
• 235000010469 Glycine max Nutrition 0.000 description 2
• 208000032008 Glycogen storage disease due to glycogen debranching enzyme deficiency Diseases 0.000 description 2
• 208000007698 Gyrate Atrophy Diseases 0.000 description 2
• 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 2
• 208000018565 Hemochromatosis Diseases 0.000 description 2
• 208000009292 Hemophilia A Diseases 0.000 description 2
• 208000003591 Hepatoerythropoietic Porphyria Diseases 0.000 description 2
• 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 2
• 208000000627 Hereditary Coproporphyria Diseases 0.000 description 2
• 208000006411 Hereditary Sensory and Motor Neuropathy Diseases 0.000 description 2
• 108010000540 Hexosaminidases Proteins 0.000 description 2
• 102000002268 Hexosaminidases Human genes 0.000 description 2
• 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 2
• 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 2
• 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 2
• 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 2
• 101001067100 Homo sapiens Uroporphyrinogen-III synthase Proteins 0.000 description 2
• 208000023105 Huntington disease Diseases 0.000 description 2
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
• 206010020575 Hyperammonaemia Diseases 0.000 description 2
• 108060003951 Immunoglobulin Proteins 0.000 description 2
• 108700005091 Immunoglobulin Genes Proteins 0.000 description 2
• 208000008498 Infantile Refsum disease Diseases 0.000 description 2
• 206010061218 Inflammation Diseases 0.000 description 2
• 102000004877 Insulin Human genes 0.000 description 2
• 108090001061 Insulin Proteins 0.000 description 2
• 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
• 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 2
• 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 2
• 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 2
• 108010050904 Interferons Proteins 0.000 description 2
• 102000014150 Interferons Human genes 0.000 description 2
• 102100020873 Interleukin-2 Human genes 0.000 description 2
• 108010002350 Interleukin-2 Proteins 0.000 description 2
• 102000004388 Interleukin-4 Human genes 0.000 description 2
• 108090000978 Interleukin-4 Proteins 0.000 description 2
• JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 2
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
• 108700006159 Long-chain acyl-CoA dehydrogenase deficiency Proteins 0.000 description 2
• 108700000232 Medium chain acyl CoA dehydrogenase deficiency Proteins 0.000 description 2
• 208000024556 Mendelian disease Diseases 0.000 description 2
• 208000008948 Menkes Kinky Hair Syndrome Diseases 0.000 description 2
• 208000012583 Menkes disease Diseases 0.000 description 2
• 201000011442 Metachromatic leukodystrophy Diseases 0.000 description 2
• CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 2
• VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical group COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
• 241000699660 Mus musculus Species 0.000 description 2
• 108090000742 Neurotrophin 3 Proteins 0.000 description 2
• 102000003683 Neurotrophin-4 Human genes 0.000 description 2
• 102100033857 Neurotrophin-4 Human genes 0.000 description 2
• 108700020796 Oncogene Proteins 0.000 description 2
• 102000043276 Oncogene Human genes 0.000 description 2
• 102000007981 Ornithine carbamoyltransferase Human genes 0.000 description 2
• 101710198224 Ornithine carbamoyltransferase, mitochondrial Proteins 0.000 description 2
• 206010031243 Osteogenesis imperfecta Diseases 0.000 description 2
• 101710116435 Outer membrane protein Proteins 0.000 description 2
• 238000010222 PCR analysis Methods 0.000 description 2
• 241000606856 Pasteurella multocida Species 0.000 description 2
• 235000019483 Peanut oil Nutrition 0.000 description 2
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
• 108010043958 Peptoids Proteins 0.000 description 2
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
• 201000011252 Phenylketonuria Diseases 0.000 description 2
• 108010004729 Phycoerythrin Proteins 0.000 description 2
• 206010035226 Plasma cell myeloma Diseases 0.000 description 2
• 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
• 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
• 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
• 239000002202 Polyethylene glycol Substances 0.000 description 2
• 108010039918 Polylysine Proteins 0.000 description 2
• 241000097929 Porphyria Species 0.000 description 2
• 208000033141 Porphyria variegata Diseases 0.000 description 2
• 208000010642 Porphyrias Diseases 0.000 description 2
• WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
• 108700018490 Prekallikrein Deficiency Proteins 0.000 description 2
• 101800004937 Protein C Proteins 0.000 description 2
• 102000017975 Protein C Human genes 0.000 description 2
• 102100029028 Protoporphyrinogen oxidase Human genes 0.000 description 2
• 201000004681 Psoriasis Diseases 0.000 description 2
• 108091030071 RNAI Proteins 0.000 description 2
• 201000004964 Rhizomelic Chondrodysplasia Punctata Diseases 0.000 description 2
• 241001030146 Rhodotorula sp. Species 0.000 description 2
• 108010039491 Ricin Proteins 0.000 description 2
• 240000000528 Ricinus communis Species 0.000 description 2
• 235000004443 Ricinus communis Nutrition 0.000 description 2
• 101800001700 Saposin-D Proteins 0.000 description 2
• 201000002883 Scheie syndrome Diseases 0.000 description 2
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
• 238000002105 Southern blotting Methods 0.000 description 2
• 241000191940 Staphylococcus Species 0.000 description 2
• 229920002472 Starch Polymers 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
• 208000002847 Surgical Wound Diseases 0.000 description 2
• 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 2
• MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
• 108010000499 Thromboplastin Proteins 0.000 description 2
• 102000002262 Thromboplastin Human genes 0.000 description 2
• 102100033571 Tissue-type plasminogen activator Human genes 0.000 description 2
• 201000003379 Townes-Brocks syndrome Diseases 0.000 description 2
• 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
• 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
• 108010009583 Transforming Growth Factors Proteins 0.000 description 2
• 102000009618 Transforming Growth Factors Human genes 0.000 description 2
• 206010044688 Trisomy 21 Diseases 0.000 description 2
• GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
• 108090000631 Trypsin Proteins 0.000 description 2
• 102000004142 Trypsin Human genes 0.000 description 2
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
• 206010045261 Type IIa hyperlipidaemia Diseases 0.000 description 2
• 102100034397 Uroporphyrinogen-III synthase Human genes 0.000 description 2
• 201000011053 Variegate Porphyria Diseases 0.000 description 2
• 241000607626 Vibrio cholerae Species 0.000 description 2
• 108700005077 Viral Genes Proteins 0.000 description 2
• 208000018839 Wilson disease Diseases 0.000 description 2
• 241000607479 Yersinia pestis Species 0.000 description 2
• 201000004525 Zellweger Syndrome Diseases 0.000 description 2
• 208000036813 Zellweger spectrum disease Diseases 0.000 description 2
• 239000008351 acetate buffer Substances 0.000 description 2
• 229960001138 acetylsalicylic acid Drugs 0.000 description 2
• 239000013543 active substance Substances 0.000 description 2
• 230000001154 acute effect Effects 0.000 description 2
• 239000002671 adjuvant Substances 0.000 description 2
• 235000010419 agar Nutrition 0.000 description 2
• 206010001689 alkaptonuria Diseases 0.000 description 2
• 235000012211 aluminium silicate Nutrition 0.000 description 2
• 125000000539 amino acid group Chemical group 0.000 description 2
• 208000007502 anemia Diseases 0.000 description 2
• 230000003172 anti-dna Effects 0.000 description 2
• 230000002921 anti-spasmodic effect Effects 0.000 description 2
• 239000003963 antioxidant agent Substances 0.000 description 2
• 235000006708 antioxidants Nutrition 0.000 description 2
• 229940124575 antispasmodic agent Drugs 0.000 description 2
• 201000003554 argininosuccinic aciduria Diseases 0.000 description 2
• 208000006673 asthma Diseases 0.000 description 2
• 230000001580 bacterial effect Effects 0.000 description 2
• 239000000440 bentonite Substances 0.000 description 2
• 229910000278 bentonite Inorganic materials 0.000 description 2
• SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
• SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
• MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
• 230000005540 biological transmission Effects 0.000 description 2
• 238000001574 biopsy Methods 0.000 description 2
• 210000002459 blastocyst Anatomy 0.000 description 2
• 210000004369 blood Anatomy 0.000 description 2
• 239000008280 blood Substances 0.000 description 2
• 239000003114 blood coagulation factor Substances 0.000 description 2
• 229940112869 bone morphogenetic protein Drugs 0.000 description 2
• 239000006172 buffering agent Substances 0.000 description 2
• 235000019437 butane-1,3-diol Nutrition 0.000 description 2
• RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
• 235000010216 calcium carbonate Nutrition 0.000 description 2
• 229910000389 calcium phosphate Inorganic materials 0.000 description 2
• 235000011010 calcium phosphates Nutrition 0.000 description 2
• 239000001768 carboxy methyl cellulose Substances 0.000 description 2
• 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
• 229960000541 cetyl alcohol Drugs 0.000 description 2
• 230000008859 change Effects 0.000 description 2
• 239000003153 chemical reaction reagent Substances 0.000 description 2
• OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
• 230000002759 chromosomal effect Effects 0.000 description 2
• 229960004126 codeine Drugs 0.000 description 2
• 210000001072 colon Anatomy 0.000 description 2
• 239000003086 colorant Substances 0.000 description 2
• 239000002299 complementary DNA Substances 0.000 description 2
• 238000011109 contamination Methods 0.000 description 2
• 239000003433 contraceptive agent Substances 0.000 description 2
• 238000007796 conventional method Methods 0.000 description 2
• 230000001086 cytosolic effect Effects 0.000 description 2
• 230000003247 decreasing effect Effects 0.000 description 2
• 108010025838 dectin 1 Proteins 0.000 description 2
• 230000006735 deficit Effects 0.000 description 2
• 230000006866 deterioration Effects 0.000 description 2
• 206010012601 diabetes mellitus Diseases 0.000 description 2
• 238000009792 diffusion process Methods 0.000 description 2
• 239000006196 drop Substances 0.000 description 2
• 238000004520 electroporation Methods 0.000 description 2
• 230000009881 electrostatic interaction Effects 0.000 description 2
• 230000001804 emulsifying effect Effects 0.000 description 2
• 230000012202 endocytosis Effects 0.000 description 2
• 239000012645 endogenous antigen Substances 0.000 description 2
• 230000007613 environmental effect Effects 0.000 description 2
• 210000000981 epithelium Anatomy 0.000 description 2
• 201000008220 erythropoietic protoporphyria Diseases 0.000 description 2
• 229940105423 erythropoietin Drugs 0.000 description 2
• 238000012869 ethanol precipitation Methods 0.000 description 2
• BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
• 201000007382 factor V deficiency Diseases 0.000 description 2
• 201000007386 factor VII deficiency Diseases 0.000 description 2
• 201000007219 factor XI deficiency Diseases 0.000 description 2
• 229960004222 factor ix Drugs 0.000 description 2
• 229960000301 factor viii Drugs 0.000 description 2
• 239000003925 fat Substances 0.000 description 2
• 235000019197 fats Nutrition 0.000 description 2
• 238000000855 fermentation Methods 0.000 description 2
• 230000004151 fermentation Effects 0.000 description 2
• 229940012952 fibrinogen Drugs 0.000 description 2
• 239000000945 filler Substances 0.000 description 2
• 238000002073 fluorescence micrograph Methods 0.000 description 2
• 235000013355 food flavoring agent Nutrition 0.000 description 2
• 235000003599 food sweetener Nutrition 0.000 description 2
• BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
• 239000007903 gelatin capsule Substances 0.000 description 2
• 230000030279 gene silencing Effects 0.000 description 2
• 230000009368 gene silencing by RNA Effects 0.000 description 2
• 238000010353 genetic engineering Methods 0.000 description 2
• 229960002442 glucosamine Drugs 0.000 description 2
• 235000013922 glutamic acid Nutrition 0.000 description 2
• 239000004220 glutamic acid Substances 0.000 description 2
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
• 201000004543 glycogen storage disease III Diseases 0.000 description 2
• 239000008187 granular material Substances 0.000 description 2
• 230000012010 growth Effects 0.000 description 2
• 239000003102 growth factor Substances 0.000 description 2
• 239000007902 hard capsule Substances 0.000 description 2
• 208000009429 hemophilia B Diseases 0.000 description 2
• 208000021995 hereditary motor and sensory neuropathy Diseases 0.000 description 2
• FBPFZTCFMRRESA-UHFFFAOYSA-N hexane-1,2,3,4,5,6-hexol Chemical compound OCC(O)C(O)C(O)C(O)CO FBPFZTCFMRRESA-UHFFFAOYSA-N 0.000 description 2
• 229940125697 hormonal agent Drugs 0.000 description 2
• OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 2
• JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
• 230000007062 hydrolysis Effects 0.000 description 2
• 238000006460 hydrolysis reaction Methods 0.000 description 2
• 230000002209 hydrophobic effect Effects 0.000 description 2
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
• UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
• 201000011286 hyperargininemia Diseases 0.000 description 2
• 208000000522 hyperlipoproteinemia type IV Diseases 0.000 description 2
• 238000002649 immunization Methods 0.000 description 2
• 102000018358 immunoglobulin Human genes 0.000 description 2
• 239000007943 implant Substances 0.000 description 2
• 238000010348 incorporation Methods 0.000 description 2
• CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
• 208000015181 infectious disease Diseases 0.000 description 2
• 230000003960 inflammatory cascade Effects 0.000 description 2
• 230000004054 inflammatory process Effects 0.000 description 2
• 239000003112 inhibitor Substances 0.000 description 2
• 239000007972 injectable composition Substances 0.000 description 2
• 230000003993 interaction Effects 0.000 description 2
• 229940079322 interferon Drugs 0.000 description 2
• 238000001361 intraarterial administration Methods 0.000 description 2
• 238000007918 intramuscular administration Methods 0.000 description 2
• 230000002262 irrigation Effects 0.000 description 2
• 238000003973 irrigation Methods 0.000 description 2
• 238000002955 isolation Methods 0.000 description 2
• NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
• 238000011031 large-scale manufacturing process Methods 0.000 description 2
• 239000008297 liquid dosage form Substances 0.000 description 2
• 229940057995 liquid paraffin Drugs 0.000 description 2
• 208000004687 long chain acyl-CoA dehydrogenase deficiency Diseases 0.000 description 2
• 108010045758 lysosomal proteins Proteins 0.000 description 2
• 210000003712 lysosome Anatomy 0.000 description 2
• 230000001868 lysosomic effect Effects 0.000 description 2
• 210000003126 m-cell Anatomy 0.000 description 2
• 235000019359 magnesium stearate Nutrition 0.000 description 2
• 210000004962 mammalian cell Anatomy 0.000 description 2
• 208000005548 medium chain acyl-CoA dehydrogenase deficiency Diseases 0.000 description 2
• 210000004379 membrane Anatomy 0.000 description 2
• 239000012528 membrane Substances 0.000 description 2
• XJRBAMWJDBPFIM-UHFFFAOYSA-N methyl vinyl ether Chemical compound COC=C XJRBAMWJDBPFIM-UHFFFAOYSA-N 0.000 description 2
• 239000008108 microcrystalline cellulose Substances 0.000 description 2
• 229940016286 microcrystalline cellulose Drugs 0.000 description 2
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
• 210000000274 microglia Anatomy 0.000 description 2
• 238000001000 micrograph Methods 0.000 description 2
• 230000002438 mitochondrial effect Effects 0.000 description 2
• 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
• BAVYZALUXZFZLV-UHFFFAOYSA-N mono-methylamine Natural products NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
• BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
• 201000005545 motor peripheral neuropathy Diseases 0.000 description 2
• 238000000465 moulding Methods 0.000 description 2
• 201000000050 myeloid neoplasm Diseases 0.000 description 2
• 239000004081 narcotic agent Substances 0.000 description 2
• 229940097496 nasal spray Drugs 0.000 description 2
• 239000007922 nasal spray Substances 0.000 description 2
• 230000000926 neurological effect Effects 0.000 description 2
• 239000003900 neurotrophic factor Substances 0.000 description 2
• 229910052757 nitrogen Inorganic materials 0.000 description 2
• 229940053934 norethindrone Drugs 0.000 description 2
• VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 2
• 210000004940 nucleus Anatomy 0.000 description 2
• 239000002674 ointment Substances 0.000 description 2
• 208000014380 ornithine aminotransferase deficiency Diseases 0.000 description 2
• 238000004806 packaging method and process Methods 0.000 description 2
• 239000012188 paraffin wax Substances 0.000 description 2
• 229940051027 pasteurella multocida Drugs 0.000 description 2
• 102000007863 pattern recognition receptors Human genes 0.000 description 2
• 239000000312 peanut oil Substances 0.000 description 2
• DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 2
• 229920000371 poly(diallyldimethylammonium chloride) polymer Polymers 0.000 description 2
• 229920000768 polyamine Polymers 0.000 description 2
• 229920000656 polylysine Polymers 0.000 description 2
• OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
• 230000000750 progressive effect Effects 0.000 description 2
• 230000001737 promoting effect Effects 0.000 description 2
• 229960000856 protein c Drugs 0.000 description 2
• 238000002818 protein evolution Methods 0.000 description 2
• 238000009256 replacement therapy Methods 0.000 description 2
• 230000002441 reversible effect Effects 0.000 description 2
• 208000001392 short chain acyl-CoA dehydrogenase deficiency Diseases 0.000 description 2
• 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
• 239000004334 sorbic acid Substances 0.000 description 2
• 235000010199 sorbic acid Nutrition 0.000 description 2
• 229940075582 sorbic acid Drugs 0.000 description 2
• 239000000600 sorbitol Substances 0.000 description 2
• 229940063673 spermidine Drugs 0.000 description 2
• PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
• 230000003393 splenic effect Effects 0.000 description 2
• 235000019698 starch Nutrition 0.000 description 2
• 239000007858 starting material Substances 0.000 description 2
• 230000003637 steroidlike Effects 0.000 description 2
• UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
• KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
• 229910021653 sulphate ion Inorganic materials 0.000 description 2
• 239000000454 talc Substances 0.000 description 2
• 229910052623 talc Inorganic materials 0.000 description 2
• 235000012222 talc Nutrition 0.000 description 2
• 229960000814 tetanus toxoid Drugs 0.000 description 2
• ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
• 229940124597 therapeutic agent Drugs 0.000 description 2
• 230000031998 transcytosis Effects 0.000 description 2
• 238000013519 translation Methods 0.000 description 2
• 230000005945 translocation Effects 0.000 description 2
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
• 239000012588 trypsin Substances 0.000 description 2
• 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 2
• 201000007962 tyrosinemia type II Diseases 0.000 description 2
• 239000008158 vegetable oil Substances 0.000 description 2
• 201000010866 very long chain acyl-CoA dehydrogenase deficiency Diseases 0.000 description 2
• 229940118696 vibrio cholerae Drugs 0.000 description 2
• 230000003612 virological effect Effects 0.000 description 2
• 239000001993 wax Substances 0.000 description 2
• 201000002928 xanthinuria Diseases 0.000 description 2
• DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
• AKNNEGZIBPJZJG-MSOLQXFVSA-N (-)-noscapine Chemical compound CN1CCC2=CC=3OCOC=3C(OC)=C2[C@@H]1[C@@H]1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-MSOLQXFVSA-N 0.000 description 1
• FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
• LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
• OPCHFPHZPIURNA-MFERNQICSA-N (2s)-2,5-bis(3-aminopropylamino)-n-[2-(dioctadecylamino)acetyl]pentanamide Chemical compound CCCCCCCCCCCCCCCCCCN(CC(=O)NC(=O)[C@H](CCCNCCCN)NCCCN)CCCCCCCCCCCCCCCCCC OPCHFPHZPIURNA-MFERNQICSA-N 0.000 description 1
• LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 description 1
• DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
• OFMQLVRLOGHAJI-FGHAYEPSSA-N (4r,7s,10s,13r,16s,19r)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-10-[3-(diaminomethylideneamino)propyl]-7-[(1r)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-3,3-dimethyl-6,9,12,15,18 Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(=O)N[C@@H](C(SSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=CC=CC=1)(C)C)C(=O)N[C@@H]([C@H](O)C)C(N)=O)[C@@H](C)O)C1=CC=C(O)C=C1 OFMQLVRLOGHAJI-FGHAYEPSSA-N 0.000 description 1
• DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
• PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 description 1
• NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
• 229940058015 1,3-butylene glycol Drugs 0.000 description 1
• YYLPVHZCJZPFFG-UHFFFAOYSA-N 1,3-dioxa-2$l^{6}-thiacycloundecane 2,2-dioxide Chemical compound O=S1(=O)OCCCCCCCCO1 YYLPVHZCJZPFFG-UHFFFAOYSA-N 0.000 description 1
• ZHMWOVGZCINIHW-FTYOSCRSSA-N 1-D-1,2-anhydro-myo-inositol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H]2O[C@H]21 ZHMWOVGZCINIHW-FTYOSCRSSA-N 0.000 description 1
• SGNXVBOIDPPRJJ-PSASIEDQSA-N 1-[(1r,6r)-9-azabicyclo[4.2.1]non-4-en-5-yl]ethanone Chemical compound CC(=O)C1=CCC[C@@H]2CC[C@H]1N2 SGNXVBOIDPPRJJ-PSASIEDQSA-N 0.000 description 1
• IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
• BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
• WLEAHMOLLIDTKD-UHFFFAOYSA-N 2,3,4,5-tetrahydroxyhexanediamide Chemical compound NC(=O)C(O)C(O)C(O)C(O)C(N)=O WLEAHMOLLIDTKD-UHFFFAOYSA-N 0.000 description 1
• KWVJHCQQUFDPLU-YEUCEMRASA-N 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KWVJHCQQUFDPLU-YEUCEMRASA-N 0.000 description 1
• WALUVDCNGPQPOD-UHFFFAOYSA-M 2,3-di(tetradecoxy)propyl-(2-hydroxyethyl)-dimethylazanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCOCC(C[N+](C)(C)CCO)OCCCCCCCCCCCCCC WALUVDCNGPQPOD-UHFFFAOYSA-M 0.000 description 1
• QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
• MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
• SPCKHVPPRJWQRZ-UHFFFAOYSA-N 2-benzhydryloxy-n,n-dimethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 SPCKHVPPRJWQRZ-UHFFFAOYSA-N 0.000 description 1
• HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
• 150000005011 4-aminoquinolines Chemical class 0.000 description 1
• ATAJVFBUUIBIEO-UHFFFAOYSA-N 7-chloro-2,3-dihydro-1h-inden-4-ol Chemical compound OC1=CC=C(Cl)C2=C1CCC2 ATAJVFBUUIBIEO-UHFFFAOYSA-N 0.000 description 1
• 150000005012 8-aminoquinolines Chemical class 0.000 description 1
• IOEPXYJOHIZYGQ-UHFFFAOYSA-N 8-methyl-6-(4-methylpiperazin-1-yl)benzo[b][1,4]benzothiazepine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2SC2=CC=C(C)C=C12 IOEPXYJOHIZYGQ-UHFFFAOYSA-N 0.000 description 1
• 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 1
• 208000030507 AIDS Diseases 0.000 description 1
• 102100024643 ATP-binding cassette sub-family D member 1 Human genes 0.000 description 1
• 208000002618 Aarskog syndrome Diseases 0.000 description 1
• 208000033745 Aarskog-Scott syndrome Diseases 0.000 description 1
• 206010063429 Aase syndrome Diseases 0.000 description 1
• 201000004770 Ablepharon macrostomia syndrome Diseases 0.000 description 1
• 206010000234 Abortion spontaneous Diseases 0.000 description 1
• 244000215068 Acacia senegal Species 0.000 description 1
• 235000006491 Acacia senegal Nutrition 0.000 description 1
• 108090000107 Acrosin Proteins 0.000 description 1
• 241000606729 Actinobacillus equuli Species 0.000 description 1
• 206010072413 Action tremor Diseases 0.000 description 1
• 108010059616 Activins Proteins 0.000 description 1
• 102000005606 Activins Human genes 0.000 description 1
• 201000011452 Adrenoleukodystrophy Diseases 0.000 description 1
• 208000002004 Afibrinogenemia Diseases 0.000 description 1
• 201000011374 Alagille syndrome Diseases 0.000 description 1
• 206010001557 Albinism Diseases 0.000 description 1
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
• 235000019489 Almond oil Nutrition 0.000 description 1
• 201000004384 Alopecia Diseases 0.000 description 1
• 241000710929 Alphavirus Species 0.000 description 1
• 208000024985 Alport syndrome Diseases 0.000 description 1
• 208000031277 Amaurotic familial idiocy Diseases 0.000 description 1
• 108090000915 Aminopeptidases Proteins 0.000 description 1
• 102000004400 Aminopeptidases Human genes 0.000 description 1
• 239000004382 Amylase Substances 0.000 description 1
• 102000013142 Amylases Human genes 0.000 description 1
• 108010065511 Amylases Proteins 0.000 description 1
• 206010056292 Androgen-Insensitivity Syndrome Diseases 0.000 description 1
• 208000009575 Angelman syndrome Diseases 0.000 description 1
• 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
• 108010005853 Anti-Mullerian Hormone Proteins 0.000 description 1
• UIFFUZWRFRDZJC-UHFFFAOYSA-N Antimycin A1 Natural products CC1OC(=O)C(CCCCCC)C(OC(=O)CC(C)C)C(C)OC(=O)C1NC(=O)C1=CC=CC(NC=O)=C1O UIFFUZWRFRDZJC-UHFFFAOYSA-N 0.000 description 1
• NQWZLRAORXLWDN-UHFFFAOYSA-N Antimycin-A Natural products CCCCCCC(=O)OC1C(C)OC(=O)C(NC(=O)c2ccc(NC=O)cc2O)C(C)OC(=O)C1CCCC NQWZLRAORXLWDN-UHFFFAOYSA-N 0.000 description 1
• 201000005657 Antithrombin III deficiency Diseases 0.000 description 1
• 102000006991 Apolipoprotein B-100 Human genes 0.000 description 1
• 108010008150 Apolipoprotein B-100 Proteins 0.000 description 1
• 102100029470 Apolipoprotein E Human genes 0.000 description 1
• 101710095339 Apolipoprotein E Proteins 0.000 description 1
• 101710115418 Apolipoprotein(a) Proteins 0.000 description 1
• 108010071619 Apolipoproteins Proteins 0.000 description 1
• 102000007592 Apolipoproteins Human genes 0.000 description 1
• 102000018616 Apolipoproteins B Human genes 0.000 description 1
• 108010027006 Apolipoproteins B Proteins 0.000 description 1
• 108010012927 Apoprotein(a) Proteins 0.000 description 1
• 235000003911 Arachis Nutrition 0.000 description 1
• 244000105624 Arachis hypogaea Species 0.000 description 1
• 241000712891 Arenavirus Species 0.000 description 1
• 201000009695 Argentine hemorrhagic fever Diseases 0.000 description 1
• 206010062695 Arginase deficiency Diseases 0.000 description 1
• 206010003267 Arthritis reactive Diseases 0.000 description 1
• 241001225321 Aspergillus fumigatus Species 0.000 description 1
• 241000416162 Astragalus gummifer Species 0.000 description 1
• 206010003591 Ataxia Diseases 0.000 description 1
• 201000001320 Atherosclerosis Diseases 0.000 description 1
• 101800001288 Atrial natriuretic factor Proteins 0.000 description 1
• 102400001282 Atrial natriuretic peptide Human genes 0.000 description 1
• 101800001890 Atrial natriuretic peptide Proteins 0.000 description 1
• 241001465356 Atropa belladonna Species 0.000 description 1
• 229930003347 Atropine Natural products 0.000 description 1
• 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
• 206010003805 Autism Diseases 0.000 description 1
• 208000020706 Autistic disease Diseases 0.000 description 1
• 208000031212 Autoimmune polyendocrinopathy Diseases 0.000 description 1
• 206010050245 Autoimmune thrombocytopenia Diseases 0.000 description 1
• 208000003950 B-cell lymphoma Diseases 0.000 description 1
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
• 241000223775 Babesia caballi Species 0.000 description 1
• 206010062804 Basal cell naevus syndrome Diseases 0.000 description 1
• 201000000046 Beckwith-Wiedemann syndrome Diseases 0.000 description 1
• 206010004265 Benign familial pemphigus Diseases 0.000 description 1
• 208000001593 Bernard-Soulier syndrome Diseases 0.000 description 1
• 208000037663 Best vitelliform macular dystrophy Diseases 0.000 description 1
• 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
• 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
• 208000033932 Blackfan-Diamond anemia Diseases 0.000 description 1
• 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
• 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
• 102000004506 Blood Proteins Human genes 0.000 description 1
• 108010017384 Blood Proteins Proteins 0.000 description 1
• 208000005692 Bloom Syndrome Diseases 0.000 description 1
• 108030001720 Bontoxilysin Proteins 0.000 description 1
• 241000588779 Bordetella bronchiseptica Species 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 208000003508 Botulism Diseases 0.000 description 1
• 206010063292 Brain stem syndrome Diseases 0.000 description 1
• 241000589562 Brucella Species 0.000 description 1
• 241000589567 Brucella abortus Species 0.000 description 1
• 241001509299 Brucella canis Species 0.000 description 1
• 241001148106 Brucella melitensis Species 0.000 description 1
• 241000589568 Brucella ovis Species 0.000 description 1
• 241001148111 Brucella suis Species 0.000 description 1
• 206010006500 Brucellosis Diseases 0.000 description 1
• 241000722910 Burkholderia mallei Species 0.000 description 1
• 206010069747 Burkholderia mallei infection Diseases 0.000 description 1
• 208000011691 Burkitt lymphomas Diseases 0.000 description 1
• 102100031092 C-C motif chemokine 3 Human genes 0.000 description 1
• 101710155856 C-C motif chemokine 3 Proteins 0.000 description 1
• 101100501304 Caenorhabditis elegans emr-1 gene Proteins 0.000 description 1
• 102400000113 Calcitonin Human genes 0.000 description 1
• 108060001064 Calcitonin Proteins 0.000 description 1
• UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
• 241000222122 Candida albicans Species 0.000 description 1
• 241000222178 Candida tropicalis Species 0.000 description 1
• 241000282472 Canis lupus familiaris Species 0.000 description 1
• 102100028892 Cardiotrophin-1 Human genes 0.000 description 1
• 102000013658 Carnitine Acyltransferases Human genes 0.000 description 1
• 108010051527 Carnitine Acyltransferases Proteins 0.000 description 1
• 102000014914 Carrier Proteins Human genes 0.000 description 1
• 108010078791 Carrier Proteins Proteins 0.000 description 1
• 241000700198 Cavia Species 0.000 description 1
• 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
• 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
• 229930186147 Cephalosporin Natural products 0.000 description 1
• 240000008886 Ceratonia siliqua Species 0.000 description 1
• 235000013912 Ceratonia siliqua Nutrition 0.000 description 1
• 241000282693 Cercopithecidae Species 0.000 description 1
• YBSQGNFRWZKFMJ-UHFFFAOYSA-N Cerebroside B Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(C(O)C=CCCC=C(C)CCCCCCCCC)COC1OC(CO)C(O)C(O)C1O YBSQGNFRWZKFMJ-UHFFFAOYSA-N 0.000 description 1
• 201000008992 Charcot-Marie-Tooth disease type 1B Diseases 0.000 description 1
• 206010068051 Chimerism Diseases 0.000 description 1
• 241001647378 Chlamydia psittaci Species 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
• QMBJSIBWORFWQT-DFXBJWIESA-N Chlormadinone acetate Chemical compound C1=C(Cl)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 QMBJSIBWORFWQT-DFXBJWIESA-N 0.000 description 1
• 208000022411 Cholesterol-ester transfer protein deficiency Diseases 0.000 description 1
• 206010008723 Chondrodystrophy Diseases 0.000 description 1
• 102100021809 Chorionic somatomammotropin hormone 1 Human genes 0.000 description 1
• 206010008805 Chromosomal abnormalities Diseases 0.000 description 1
• 208000031404 Chromosome Aberrations Diseases 0.000 description 1
• 208000011359 Chromosome disease Diseases 0.000 description 1
• 208000017667 Chronic Disease Diseases 0.000 description 1
• 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
• 108090000317 Chymotrypsin Proteins 0.000 description 1
• 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 1
• 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 1
• 208000011835 Classic galactosemia Diseases 0.000 description 1
• 241000193163 Clostridioides difficile Species 0.000 description 1
• 241001509396 Clostridium botulinum D Species 0.000 description 1
• 241001509506 Clostridium botulinum E Species 0.000 description 1
• 241000206044 Clostridium chauvoei Species 0.000 description 1
• 241000186581 Clostridium novyi Species 0.000 description 1
• 241000193466 Clostridium septicum Species 0.000 description 1
• 241000193449 Clostridium tetani Species 0.000 description 1
• 102100026735 Coagulation factor VIII Human genes 0.000 description 1
• 206010053567 Coagulopathies Diseases 0.000 description 1
• 108020004705 Codon Proteins 0.000 description 1
• 208000001353 Coffin-Lowry syndrome Diseases 0.000 description 1
• 206010009900 Colitis ulcerative Diseases 0.000 description 1
• 102000008186 Collagen Human genes 0.000 description 1
• 108010035532 Collagen Proteins 0.000 description 1
• 206010009944 Colon cancer Diseases 0.000 description 1
• 206010010099 Combined immunodeficiency Diseases 0.000 description 1
• 108010062580 Concanavalin A Proteins 0.000 description 1
• ZHMWOVGZCINIHW-SPHYCDKFSA-N Conduritol-beta-epoxide Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C2OC21 ZHMWOVGZCINIHW-SPHYCDKFSA-N 0.000 description 1
• 206010053138 Congenital aplastic anaemia Diseases 0.000 description 1
• 208000011029 Congenital factor XII deficiency Diseases 0.000 description 1
• 102000012437 Copper-Transporting ATPases Human genes 0.000 description 1
• 201000009343 Cornelia de Lange syndrome Diseases 0.000 description 1
• 241000186227 Corynebacterium diphtheriae Species 0.000 description 1
• 208000012609 Cowden disease Diseases 0.000 description 1
• 201000002847 Cowden syndrome Diseases 0.000 description 1
• 241001445332 Coxiella <snail> Species 0.000 description 1
• 208000001727 Craniofrontonasal dysplasia Diseases 0.000 description 1
• 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
• 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
• 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
• 208000001819 Crigler-Najjar Syndrome Diseases 0.000 description 1
• 241000223936 Cryptosporidium parvum Species 0.000 description 1
• 244000007835 Cyamopsis tetragonoloba Species 0.000 description 1
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
• 230000033616 DNA repair Effects 0.000 description 1
• 208000003471 De Lange Syndrome Diseases 0.000 description 1
• 206010011878 Deafness Diseases 0.000 description 1
• 108010053770 Deoxyribonucleases Proteins 0.000 description 1
• 102000016911 Deoxyribonucleases Human genes 0.000 description 1
• 206010012335 Dependence Diseases 0.000 description 1
• 208000000398 DiGeorge Syndrome Diseases 0.000 description 1
• 201000004449 Diamond-Blackfan anemia Diseases 0.000 description 1
• 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
• LVHOURKCKUYIGK-RGUJTQARSA-N Dimethisterone Chemical compound C1([C@@H](C)C2)=CC(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C#CC)(O)[C@@]2(C)CC1 LVHOURKCKUYIGK-RGUJTQARSA-N 0.000 description 1
• 102000016607 Diphtheria Toxin Human genes 0.000 description 1
• 108010053187 Diphtheria Toxin Proteins 0.000 description 1
• 208000001925 Dubowitz syndrome Diseases 0.000 description 1
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
• 102000001301 EGF receptor Human genes 0.000 description 1
• 108060006698 EGF receptor Proteins 0.000 description 1
• 239000004278 EU approved seasoning Substances 0.000 description 1
• 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 1
• 208000030820 Ebola disease Diseases 0.000 description 1
• LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
• 241000196324 Embryophyta Species 0.000 description 1
• BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 1
• 108050004280 Epsilon toxin Proteins 0.000 description 1
• 241000701081 Equid alphaherpesvirus 1 Species 0.000 description 1
• 241000283086 Equidae Species 0.000 description 1
• 241000710803 Equine arteritis virus Species 0.000 description 1
• 101000867232 Escherichia coli Heat-stable enterotoxin II Proteins 0.000 description 1
• DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
• BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
• 206010067141 Faciodigitogenital dysplasia Diseases 0.000 description 1
• 206010016075 Factor I deficiency Diseases 0.000 description 1
• 206010016077 Factor IX deficiency Diseases 0.000 description 1
• 108010014172 Factor V Proteins 0.000 description 1
• 201000003542 Factor VIII deficiency Diseases 0.000 description 1
• 206010016207 Familial Mediterranean fever Diseases 0.000 description 1
• 208000037574 Familial benign chronic pemphigus Diseases 0.000 description 1
• 206010059183 Familial hypertriglyceridaemia Diseases 0.000 description 1
• 201000004939 Fanconi anemia Diseases 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
• 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
• 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
• 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
• 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
• 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
• 239000004606 Fillers/Extenders Substances 0.000 description 1
• 241000711950 Filoviridae Species 0.000 description 1
• 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
• 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
• 241000589602 Francisella tularensis Species 0.000 description 1
• 208000024412 Friedreich ataxia Diseases 0.000 description 1
• 229930091371 Fructose Natural products 0.000 description 1
• 239000005715 Fructose Substances 0.000 description 1
• RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
• 230000005526 G1 to G0 transition Effects 0.000 description 1
• 102100028260 Gamma-secretase subunit PEN-2 Human genes 0.000 description 1
• 241000207201 Gardnerella vaginalis Species 0.000 description 1
• 208000020322 Gaucher disease type I Diseases 0.000 description 1
• 229930182566 Gentamicin Natural products 0.000 description 1
• CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
• 208000009139 Gilbert Disease Diseases 0.000 description 1
• 208000022412 Gilbert syndrome Diseases 0.000 description 1
• 201000003641 Glanders Diseases 0.000 description 1
• 208000010412 Glaucoma Diseases 0.000 description 1
• 102400000321 Glucagon Human genes 0.000 description 1
• 108060003199 Glucagon Proteins 0.000 description 1
• 229920002581 Glucomannan Polymers 0.000 description 1
• 102000004366 Glucosidases Human genes 0.000 description 1
• 108010056771 Glucosidases Proteins 0.000 description 1
• 239000004471 Glycine Substances 0.000 description 1
• 244000068988 Glycine max Species 0.000 description 1
• 102000007390 Glycogen Phosphorylase Human genes 0.000 description 1
• 108010046163 Glycogen Phosphorylase Proteins 0.000 description 1
• 206010053249 Glycogen Storage Disease Type IV Diseases 0.000 description 1
• 208000006562 Glycogen Storage Disease Type VII Diseases 0.000 description 1
• 102100029481 Glycogen phosphorylase, liver form Human genes 0.000 description 1
• 208000011123 Glycogen storage disease due to glycogen branching enzyme deficiency Diseases 0.000 description 1
• 208000032002 Glycogen storage disease due to liver glycogen phosphorylase deficiency Diseases 0.000 description 1
• 208000032000 Glycogen storage disease due to muscle glycogen phosphorylase deficiency Diseases 0.000 description 1
• 208000031926 Glycogen storage disease due to muscle phosphofructokinase deficiency Diseases 0.000 description 1
• 206010018464 Glycogen storage disease type I Diseases 0.000 description 1
• 206010053250 Glycogen storage disease type III Diseases 0.000 description 1
• 206010018462 Glycogen storage disease type V Diseases 0.000 description 1
• 206010053240 Glycogen storage disease type VI Diseases 0.000 description 1
• 229930186217 Glycolipid Natural products 0.000 description 1
• 201000004299 Goldberg-Shprintzen syndrome Diseases 0.000 description 1
• 102000006771 Gonadotropins Human genes 0.000 description 1
• 108010086677 Gonadotropins Proteins 0.000 description 1
• 208000031995 Gorlin syndrome Diseases 0.000 description 1
• 201000005569 Gout Diseases 0.000 description 1
• 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
• 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
• 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
• 206010018693 Granuloma inguinale Diseases 0.000 description 1
• 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
• 208000003807 Graves Disease Diseases 0.000 description 1
• 208000015023 Graves' disease Diseases 0.000 description 1
• 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 1
• 229920002907 Guar gum Polymers 0.000 description 1
• 229920000084 Gum arabic Polymers 0.000 description 1
• 208000034596 Gyrate atrophy of choroid and retina Diseases 0.000 description 1
• 241000606768 Haemophilus influenzae Species 0.000 description 1
• 206010061192 Haemorrhagic fever Diseases 0.000 description 1
• 208000027655 Hailey-Hailey disease Diseases 0.000 description 1
• 208000012777 Hartnup Disease Diseases 0.000 description 1
• 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
• 206010019463 Hemihypertrophy Diseases 0.000 description 1
• 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
• 208000031220 Hemophilia Diseases 0.000 description 1
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
• 206010019878 Hereditary fructose intolerance Diseases 0.000 description 1
• 208000033981 Hereditary haemochromatosis Diseases 0.000 description 1
• 208000017095 Hereditary nonpolyposis colon cancer Diseases 0.000 description 1
• 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
• 108700028608 Histidinemia Proteins 0.000 description 1
• 102000006947 Histones Human genes 0.000 description 1
• 108010033040 Histones Proteins 0.000 description 1
• 241001272567 Hominoidea Species 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 1
• 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
• 101000579663 Homo sapiens Gamma-secretase subunit PEN-2 Proteins 0.000 description 1
• 101000700616 Homo sapiens Glycogen phosphorylase, liver form Proteins 0.000 description 1
• 101000614436 Homo sapiens Keratin, type I cytoskeletal 14 Proteins 0.000 description 1
• 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
• 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 1
• 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
• 206010020365 Homocystinuria Diseases 0.000 description 1
• 108010000521 Human Growth Hormone Proteins 0.000 description 1
• 102000002265 Human Growth Hormone Human genes 0.000 description 1
• 239000000854 Human Growth Hormone Substances 0.000 description 1
• 108010070875 Human Immunodeficiency Virus tat Gene Products Proteins 0.000 description 1
• 108090000144 Human Proteins Proteins 0.000 description 1
• 102000003839 Human Proteins Human genes 0.000 description 1
• 108091006905 Human Serum Albumin Proteins 0.000 description 1
• 102000008100 Human Serum Albumin Human genes 0.000 description 1
• 108010003272 Hyaluronate lyase Proteins 0.000 description 1
• 102000001974 Hyaluronidases Human genes 0.000 description 1
• RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
• 206010020608 Hypercoagulation Diseases 0.000 description 1
• 208000001748 Hyperlipoproteinemia Type V Diseases 0.000 description 1
• 206010020772 Hypertension Diseases 0.000 description 1
• 201000004408 Hypobetalipoproteinemia Diseases 0.000 description 1
• 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
• 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
• 108010008212 Integrin alpha4beta1 Proteins 0.000 description 1
• 108010040765 Integrin alphaV Proteins 0.000 description 1
• 102000008607 Integrin beta3 Human genes 0.000 description 1
• 108010020950 Integrin beta3 Proteins 0.000 description 1
• 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
• 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
• 102000006992 Interferon-alpha Human genes 0.000 description 1
• 108010047761 Interferon-alpha Proteins 0.000 description 1
• 102000003996 Interferon-beta Human genes 0.000 description 1
• 108090000467 Interferon-beta Proteins 0.000 description 1
• 102000008070 Interferon-gamma Human genes 0.000 description 1
• 108010074328 Interferon-gamma Proteins 0.000 description 1
• 102000003814 Interleukin-10 Human genes 0.000 description 1
• 108090000174 Interleukin-10 Proteins 0.000 description 1
• 102000003815 Interleukin-11 Human genes 0.000 description 1
• 108090000177 Interleukin-11 Proteins 0.000 description 1
• 102000013462 Interleukin-12 Human genes 0.000 description 1
• 108010065805 Interleukin-12 Proteins 0.000 description 1
• 102000003816 Interleukin-13 Human genes 0.000 description 1
• 108090000176 Interleukin-13 Proteins 0.000 description 1
• 102000003812 Interleukin-15 Human genes 0.000 description 1
• 108090000172 Interleukin-15 Proteins 0.000 description 1
• 102000000646 Interleukin-3 Human genes 0.000 description 1
• 108010002386 Interleukin-3 Proteins 0.000 description 1
• 102100039897 Interleukin-5 Human genes 0.000 description 1
• 108010002616 Interleukin-5 Proteins 0.000 description 1
• 102000004889 Interleukin-6 Human genes 0.000 description 1
• 108090001005 Interleukin-6 Proteins 0.000 description 1
• 102100021592 Interleukin-7 Human genes 0.000 description 1
• 108010002586 Interleukin-7 Proteins 0.000 description 1
• 102100026871 Interleukin-9 Human genes 0.000 description 1
• 108010002335 Interleukin-9 Proteins 0.000 description 1
• LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
• 241000581650 Ivesia Species 0.000 description 1
• 208000007367 Kabuki syndrome Diseases 0.000 description 1
• 208000017924 Klinefelter Syndrome Diseases 0.000 description 1
• WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
• WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
• 208000023768 LCAT deficiency Diseases 0.000 description 1
• 108010001831 LDL receptors Proteins 0.000 description 1
• MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 1
• 206010023927 Lassa fever Diseases 0.000 description 1
• 208000003465 Lecithin Cholesterol Acyltransferase Deficiency Diseases 0.000 description 1
• 208000006136 Leigh Disease Diseases 0.000 description 1
• 208000017507 Leigh syndrome Diseases 0.000 description 1
• 241000589902 Leptospira Species 0.000 description 1
• 208000009625 Lesch-Nyhan syndrome Diseases 0.000 description 1
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
• 102000004058 Leukemia inhibitory factor Human genes 0.000 description 1
• 108090000581 Leukemia inhibitory factor Proteins 0.000 description 1
• 241000144128 Lichtheimia corymbifera Species 0.000 description 1
• 102000004882 Lipase Human genes 0.000 description 1
• 108090001060 Lipase Proteins 0.000 description 1
• 239000004367 Lipase Substances 0.000 description 1
• 102000004895 Lipoproteins Human genes 0.000 description 1
• 108090001030 Lipoproteins Proteins 0.000 description 1
• 241000186779 Listeria monocytogenes Species 0.000 description 1
• 208000035752 Live birth Diseases 0.000 description 1
• 108010027062 Long-Chain Acyl-CoA Dehydrogenase Proteins 0.000 description 1
• 102000018653 Long-Chain Acyl-CoA Dehydrogenase Human genes 0.000 description 1
• 102100021644 Long-chain specific acyl-CoA dehydrogenase, mitochondrial Human genes 0.000 description 1
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
• 239000006137 Luria-Bertani broth Substances 0.000 description 1
• 102000009151 Luteinizing Hormone Human genes 0.000 description 1
• 108010073521 Luteinizing Hormone Proteins 0.000 description 1
• YNVGQYHLRCDXFQ-XGXHKTLJSA-N Lynestrenol Chemical compound C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 YNVGQYHLRCDXFQ-XGXHKTLJSA-N 0.000 description 1
• 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
• 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
• 102000009571 Macrophage Inflammatory Proteins Human genes 0.000 description 1
• 108010009474 Macrophage Inflammatory Proteins Proteins 0.000 description 1
• 235000019759 Maize starch Nutrition 0.000 description 1
• 240000003183 Manihot esculenta Species 0.000 description 1
• 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
• 241001293418 Mannheimia haemolytica Species 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 102000001696 Mannosidases Human genes 0.000 description 1
• 108010054377 Mannosidases Proteins 0.000 description 1
• 208000000932 Marburg Virus Disease Diseases 0.000 description 1
• 201000011013 Marburg hemorrhagic fever Diseases 0.000 description 1
• ZPXSCAKFGYXMGA-UHFFFAOYSA-N Mazindol Chemical compound N12CCN=C2C2=CC=CC=C2C1(O)C1=CC=C(Cl)C=C1 ZPXSCAKFGYXMGA-UHFFFAOYSA-N 0.000 description 1
• 108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 description 1
• 102000003939 Membrane transport proteins Human genes 0.000 description 1
• 108090000301 Membrane transport proteins Proteins 0.000 description 1
• XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 1
• NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 description 1
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
• 206010059521 Methylmalonic aciduria Diseases 0.000 description 1
• 231100000757 Microbial toxin Toxicity 0.000 description 1
• 108090000143 Mouse Proteins Proteins 0.000 description 1
• 208000008770 Multiple Hamartoma Syndrome Diseases 0.000 description 1
• 208000000149 Multiple Sulfatase Deficiency Disease Diseases 0.000 description 1
• 208000035032 Multiple sulfatase deficiency Diseases 0.000 description 1
• 102000016943 Muramidase Human genes 0.000 description 1
• 108010014251 Muramidase Proteins 0.000 description 1
• 241000714177 Murine leukemia virus Species 0.000 description 1
• 101100335081 Mus musculus Flt3 gene Proteins 0.000 description 1
• 101100341510 Mus musculus Itgal gene Proteins 0.000 description 1
• 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
• 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
• 241000202955 Mycoplasma bovigenitalium Species 0.000 description 1
• 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
• 206010068871 Myotonic dystrophy Diseases 0.000 description 1
• 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
• 108700043217 N-acetyl glutamate synthetase deficiency Proteins 0.000 description 1
• 125000003047 N-acetyl group Chemical group 0.000 description 1
• 108010049175 N-substituted Glycines Proteins 0.000 description 1
• 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
• 229930193140 Neomycin Natural products 0.000 description 1
• 108090000028 Neprilysin Proteins 0.000 description 1
• 102000003729 Neprilysin Human genes 0.000 description 1
• 102000015336 Nerve Growth Factor Human genes 0.000 description 1
• 208000009905 Neurofibromatoses Diseases 0.000 description 1
• 208000002537 Neuronal Ceroid-Lipofuscinoses Diseases 0.000 description 1
• 108090000095 Neurotrophin-6 Proteins 0.000 description 1
• 241000526636 Nipah henipavirus Species 0.000 description 1
• SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
• 239000000006 Nitroglycerin Substances 0.000 description 1
• 206010029748 Noonan syndrome Diseases 0.000 description 1
• ICTXHFFSOAJUMG-SLHNCBLASA-N Norethynodrel Chemical compound C1CC(=O)CC2=C1[C@H]1CC[C@](C)([C@](CC3)(O)C#C)[C@@H]3[C@@H]1CC2 ICTXHFFSOAJUMG-SLHNCBLASA-N 0.000 description 1
• 201000002892 Oroticaciduria Diseases 0.000 description 1
• 241000150452 Orthohantavirus Species 0.000 description 1
• 206010033128 Ovarian cancer Diseases 0.000 description 1
• 206010061535 Ovarian neoplasm Diseases 0.000 description 1
• 239000004100 Oxytetracycline Substances 0.000 description 1
• 108091006006 PEGylated Proteins Proteins 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 241000282579 Pan Species 0.000 description 1
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
• 229930040373 Paraformaldehyde Natural products 0.000 description 1
• 102000003982 Parathyroid hormone Human genes 0.000 description 1
• 108090000445 Parathyroid hormone Proteins 0.000 description 1
• 208000018737 Parkinson disease Diseases 0.000 description 1
• 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 208000004843 Pendred Syndrome Diseases 0.000 description 1
• 229930182555 Penicillin Natural products 0.000 description 1
• RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 description 1
• 201000005702 Pertussis Diseases 0.000 description 1
• BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
• 208000016012 Phenotypic abnormality Diseases 0.000 description 1
• 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 description 1
• 108010003044 Placental Lactogen Proteins 0.000 description 1
• 239000000381 Placental Lactogen Substances 0.000 description 1
• 206010035148 Plague Diseases 0.000 description 1
• 231100000742 Plant toxin Toxicity 0.000 description 1
• 102000001938 Plasminogen Activators Human genes 0.000 description 1
• 108010001014 Plasminogen Activators Proteins 0.000 description 1
• 108010010336 Platelet Membrane Glycoproteins Proteins 0.000 description 1
• 102000015795 Platelet Membrane Glycoproteins Human genes 0.000 description 1
• 206010073391 Platelet dysfunction Diseases 0.000 description 1
• 206010035669 Pneumonia aspiration Diseases 0.000 description 1
• 229920001244 Poly(D,L-lactide) Polymers 0.000 description 1
• 229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
• 229920002732 Polyanhydride Polymers 0.000 description 1
• 108010020346 Polyglutamic Acid Proteins 0.000 description 1
• 229920001710 Polyorthoester Polymers 0.000 description 1
• 239000004793 Polystyrene Substances 0.000 description 1
• 201000010769 Prader-Willi syndrome Diseases 0.000 description 1
• 241000932075 Priacanthus hamrur Species 0.000 description 1
• 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
• 108010076181 Proinsulin Proteins 0.000 description 1
• 108010057464 Prolactin Proteins 0.000 description 1
• 102000003946 Prolactin Human genes 0.000 description 1
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
• OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
• 206010060862 Prostate cancer Diseases 0.000 description 1
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
• 201000005660 Protein C Deficiency Diseases 0.000 description 1
• 206010051292 Protein S Deficiency Diseases 0.000 description 1
• 208000007531 Proteus syndrome Diseases 0.000 description 1
• 108010094028 Prothrombin Proteins 0.000 description 1
• 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
• 108010022461 Pseudomonas aeruginosa pseudolysin Proteins 0.000 description 1
• 206010037688 Q fever Diseases 0.000 description 1
• 241000700159 Rattus Species 0.000 description 1
• 101001039269 Rattus norvegicus Glycine N-methyltransferase Proteins 0.000 description 1
• 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
• 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 description 1
• 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 1
• 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 description 1
• 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 description 1
• 102000018120 Recombinases Human genes 0.000 description 1
• 108010091086 Recombinases Proteins 0.000 description 1
• 208000005587 Refsum Disease Diseases 0.000 description 1
• 102400000834 Relaxin A chain Human genes 0.000 description 1
• 101800000074 Relaxin A chain Proteins 0.000 description 1
• 102400000610 Relaxin B chain Human genes 0.000 description 1
• 101710109558 Relaxin B chain Proteins 0.000 description 1
• 206010038478 Renal lithiasis Diseases 0.000 description 1
• LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
• QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
• 206010038669 Respiratory arrest Diseases 0.000 description 1
• 206010057190 Respiratory tract infections Diseases 0.000 description 1
• 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
• 201000000582 Retinoblastoma Diseases 0.000 description 1
• 208000006289 Rett Syndrome Diseases 0.000 description 1
• 241000158504 Rhodococcus hoagii Species 0.000 description 1
• 241000223252 Rhodotorula Species 0.000 description 1
• 108010083644 Ribonucleases Proteins 0.000 description 1
• 102000006382 Ribonucleases Human genes 0.000 description 1
• 241000283984 Rodentia Species 0.000 description 1
• 208000020619 Rotor syndrome Diseases 0.000 description 1
• 206010053694 Saccadic eye movement Diseases 0.000 description 1
• 241000607142 Salmonella Species 0.000 description 1
• 241000607662 Salmonella enterica subsp. enterica serovar Abortusequi Species 0.000 description 1
• 241000522522 Salmonella enterica subsp. enterica serovar Abortusovis Species 0.000 description 1
• 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
• 208000034189 Sclerosis Diseases 0.000 description 1
• 108010071390 Serum Albumin Proteins 0.000 description 1
• 102000007562 Serum Albumin Human genes 0.000 description 1
• 235000003434 Sesamum indicum Nutrition 0.000 description 1
• 244000040738 Sesamum orientale Species 0.000 description 1
• 241000607764 Shigella dysenteriae Species 0.000 description 1
• 108700017825 Short chain Acyl CoA dehydrogenase deficiency Proteins 0.000 description 1
• 101710084578 Short neurotoxin 1 Proteins 0.000 description 1
• 208000021386 Sjogren Syndrome Diseases 0.000 description 1
• 201000001828 Sly syndrome Diseases 0.000 description 1
• 208000001203 Smallpox Diseases 0.000 description 1
• 229920002125 Sokalan® Polymers 0.000 description 1
• 235000002595 Solanum tuberosum Nutrition 0.000 description 1
• 244000061456 Solanum tuberosum Species 0.000 description 1
• 102100022831 Somatoliberin Human genes 0.000 description 1
• 101710142969 Somatoliberin Proteins 0.000 description 1
• 238000000944 Soxhlet extraction Methods 0.000 description 1
• 201000010829 Spina bifida Diseases 0.000 description 1
• 208000006097 Spinal Dysraphism Diseases 0.000 description 1
• 208000009415 Spinocerebellar Ataxias Diseases 0.000 description 1
• 101100288418 Staphylococcus xylosus lacP gene Proteins 0.000 description 1
• 235000021355 Stearic acid Nutrition 0.000 description 1
• SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
• 241000193990 Streptococcus sp. 'group B' Species 0.000 description 1
• 102000019259 Succinate Dehydrogenase Human genes 0.000 description 1
• 108010012901 Succinate Dehydrogenase Proteins 0.000 description 1
• 241000282898 Sus scrofa Species 0.000 description 1
• 239000000150 Sympathomimetic Substances 0.000 description 1
• 206010042971 T-cell lymphoma Diseases 0.000 description 1
• 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 1
• SEQDDYPDSLOBDC-UHFFFAOYSA-N Temazepam Chemical compound N=1C(O)C(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 SEQDDYPDSLOBDC-UHFFFAOYSA-N 0.000 description 1
• PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 1
• 208000002903 Thalassemia Diseases 0.000 description 1
• 241000906446 Theraps Species 0.000 description 1
• KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 description 1
• FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
• 108090000190 Thrombin Proteins 0.000 description 1
• 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
• 102000036693 Thrombopoietin Human genes 0.000 description 1
• 108010041111 Thrombopoietin Proteins 0.000 description 1
• 102000011923 Thyrotropin Human genes 0.000 description 1
• 108010061174 Thyrotropin Proteins 0.000 description 1
• 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
• 108050006955 Tissue-type plasminogen activator Proteins 0.000 description 1
• 208000035317 Total hypoxanthine-guanine phosphoribosyl transferase deficiency Diseases 0.000 description 1
• 101710182532 Toxin a Proteins 0.000 description 1
• 241000223997 Toxoplasma gondii Species 0.000 description 1
• 229920001615 Tragacanth Polymers 0.000 description 1
• 102000011117 Transforming Growth Factor beta2 Human genes 0.000 description 1
• 102400001320 Transforming growth factor alpha Human genes 0.000 description 1
• 101800004564 Transforming growth factor alpha Proteins 0.000 description 1
• 101800000304 Transforming growth factor beta-2 Proteins 0.000 description 1
• 102000056172 Transforming growth factor beta-3 Human genes 0.000 description 1
• 108090000097 Transforming growth factor beta-3 Proteins 0.000 description 1
• 108700019146 Transgenes Proteins 0.000 description 1
• 206010044565 Tremor Diseases 0.000 description 1
• 241000589884 Treponema pallidum Species 0.000 description 1
• 241000224527 Trichomonas vaginalis Species 0.000 description 1
• UFLGIAIHIAPJJC-UHFFFAOYSA-N Tripelennamine Chemical compound C=1C=CC=NC=1N(CCN(C)C)CC1=CC=CC=C1 UFLGIAIHIAPJJC-UHFFFAOYSA-N 0.000 description 1
• 239000007983 Tris buffer Substances 0.000 description 1
• 241001058196 Tritrichomonas foetus Species 0.000 description 1
• 241000186064 Trueperella pyogenes Species 0.000 description 1
• 241000223089 Trypanosoma equiperdum Species 0.000 description 1
• 208000026911 Tuberous sclerosis complex Diseases 0.000 description 1
• 208000034784 Tularaemia Diseases 0.000 description 1
• 102000015098 Tumor Suppressor Protein p53 Human genes 0.000 description 1
• 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 1
• 102100040247 Tumor necrosis factor Human genes 0.000 description 1
• 208000026928 Turner syndrome Diseases 0.000 description 1
• 108700017798 Type I Xanthinuria Proteins 0.000 description 1
• 206010045254 Type II hyperlipidaemia Diseases 0.000 description 1
• 208000035169 Tyrosinemia type 2 Diseases 0.000 description 1
• 208000010165 Tyrosinosis Diseases 0.000 description 1
• 201000006704 Ulcerative Colitis Diseases 0.000 description 1
• 108010041865 Ulex europaeus lectins Proteins 0.000 description 1
• 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
• 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
• 208000014769 Usher Syndromes Diseases 0.000 description 1
• 241000700647 Variola virus Species 0.000 description 1
• 206010047115 Vasculitis Diseases 0.000 description 1
• OIRDTQYFTABQOQ-UHTZMRCNSA-N Vidarabine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O OIRDTQYFTABQOQ-UHTZMRCNSA-N 0.000 description 1
• 208000026724 Waardenburg syndrome Diseases 0.000 description 1
• 201000003790 Weaver syndrome Diseases 0.000 description 1
• 201000011032 Werner Syndrome Diseases 0.000 description 1
• 208000005466 Western Equine Encephalomyelitis Diseases 0.000 description 1
• 201000005806 Western equine encephalitis Diseases 0.000 description 1
• 108091005971 Wild-type GFP Proteins 0.000 description 1
• 206010049644 Williams syndrome Diseases 0.000 description 1
• 208000016807 X-linked intellectual disability-macrocephaly-macroorchidism syndrome Diseases 0.000 description 1
• 208000018818 Xanthinuria type I Diseases 0.000 description 1
• 208000003152 Yellow Fever Diseases 0.000 description 1
• HOBWAPHTEJGALG-JKCMADFCSA-N [(1r,5s)-8-methyl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate;sulfate Chemical compound [O-]S([O-])(=O)=O.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1 HOBWAPHTEJGALG-JKCMADFCSA-N 0.000 description 1
• WERKSKAQRVDLDW-ANOHMWSOSA-N [(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO WERKSKAQRVDLDW-ANOHMWSOSA-N 0.000 description 1
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
• 208000004622 abetalipoproteinemia Diseases 0.000 description 1
• 230000002159 abnormal effect Effects 0.000 description 1
• 239000003655 absorption accelerator Substances 0.000 description 1
• 238000000862 absorption spectrum Methods 0.000 description 1
• 235000010489 acacia gum Nutrition 0.000 description 1
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
• 208000008919 achondroplasia Diseases 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 201000007047 acrodysostosis Diseases 0.000 description 1
• 230000004913 activation Effects 0.000 description 1
• 239000000488 activin Substances 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 230000000996 additive effect Effects 0.000 description 1
• 210000002534 adenoid Anatomy 0.000 description 1
• 239000003463 adsorbent Substances 0.000 description 1
• 208000030597 adult Refsum disease Diseases 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 230000001476 alcoholic effect Effects 0.000 description 1
• 229930013930 alkaloid Natural products 0.000 description 1
• 125000002947 alkylene group Chemical group 0.000 description 1
• 229960003459 allopurinol Drugs 0.000 description 1
• OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
• 239000008168 almond oil Substances 0.000 description 1
• 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 description 1
• 201000006288 alpha thalassemia Diseases 0.000 description 1
• WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
• SHZGCJCMOBCMKK-SXUWKVJYSA-N alpha-L-fucose Chemical group C[C@@H]1O[C@@H](O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-SXUWKVJYSA-N 0.000 description 1
• 201000008333 alpha-mannosidosis Diseases 0.000 description 1
• AKNNEGZIBPJZJG-UHFFFAOYSA-N alpha-noscapine Natural products CN1CCC2=CC=3OCOC=3C(OC)=C2C1C1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-UHFFFAOYSA-N 0.000 description 1
• AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
• 229910052782 aluminium Inorganic materials 0.000 description 1
• XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
• 235000010210 aluminium Nutrition 0.000 description 1
• WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
• 229940077484 ammonium bromide Drugs 0.000 description 1
• 150000003863 ammonium salts Chemical class 0.000 description 1
• AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
• 229960000723 ampicillin Drugs 0.000 description 1
• 239000003708 ampul Substances 0.000 description 1
• 235000019418 amylase Nutrition 0.000 description 1
• 229940035676 analgesics Drugs 0.000 description 1
• 239000012491 analyte Substances 0.000 description 1
• 210000003484 anatomy Anatomy 0.000 description 1
• 239000003948 anatoxin Substances 0.000 description 1
• 210000004102 animal cell Anatomy 0.000 description 1
• 238000010171 animal model Methods 0.000 description 1
• 231100000659 animal toxin Toxicity 0.000 description 1
• 239000003945 anionic surfactant Substances 0.000 description 1
• 230000000954 anitussive effect Effects 0.000 description 1
• 239000000730 antalgic agent Substances 0.000 description 1
• 230000000844 anti-bacterial effect Effects 0.000 description 1
• 230000001455 anti-clotting effect Effects 0.000 description 1
• 230000001773 anti-convulsant effect Effects 0.000 description 1
• 230000003474 anti-emetic effect Effects 0.000 description 1
• 229940121363 anti-inflammatory agent Drugs 0.000 description 1
• 239000002260 anti-inflammatory agent Substances 0.000 description 1
• 239000000868 anti-mullerian hormone Substances 0.000 description 1
• 238000011394 anticancer treatment Methods 0.000 description 1
• 229940125681 anticonvulsant agent Drugs 0.000 description 1
• 239000001961 anticonvulsive agent Substances 0.000 description 1
• 239000002111 antiemetic agent Substances 0.000 description 1
• 229940125683 antiemetic agent Drugs 0.000 description 1
• 239000003429 antifungal agent Substances 0.000 description 1
• 229940121375 antifungal agent Drugs 0.000 description 1
• 230000030741 antigen processing and presentation Effects 0.000 description 1
• 210000000612 antigen-presenting cell Anatomy 0.000 description 1
• 229940125715 antihistaminic agent Drugs 0.000 description 1
• 239000000739 antihistaminic agent Substances 0.000 description 1
• 239000002220 antihypertensive agent Substances 0.000 description 1
• 239000003430 antimalarial agent Substances 0.000 description 1
• 229940033495 antimalarials Drugs 0.000 description 1
• 229940125684 antimigraine agent Drugs 0.000 description 1
• 239000002282 antimigraine agent Substances 0.000 description 1
• UIFFUZWRFRDZJC-SBOOETFBSA-N antimycin A Chemical compound C[C@H]1OC(=O)[C@H](CCCCCC)[C@@H](OC(=O)CC(C)C)[C@H](C)OC(=O)[C@H]1NC(=O)C1=CC=CC(NC=O)=C1O UIFFUZWRFRDZJC-SBOOETFBSA-N 0.000 description 1
• PVEVXUMVNWSNIG-UHFFFAOYSA-N antimycin A3 Natural products CC1OC(=O)C(CCCC)C(OC(=O)CC(C)C)C(C)OC(=O)C1NC(=O)C1=CC=CC(NC=O)=C1O PVEVXUMVNWSNIG-UHFFFAOYSA-N 0.000 description 1
• 239000002246 antineoplastic agent Substances 0.000 description 1
• 229940125688 antiparkinson agent Drugs 0.000 description 1
• 239000000939 antiparkinson agent Substances 0.000 description 1
• 229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 1
• 239000003434 antitussive agent Substances 0.000 description 1
• 229940124584 antitussives Drugs 0.000 description 1
• 239000008135 aqueous vehicle Substances 0.000 description 1
• 206010003246 arthritis Diseases 0.000 description 1
• 239000011668 ascorbic acid Substances 0.000 description 1
• 235000010323 ascorbic acid Nutrition 0.000 description 1
• 229960005070 ascorbic acid Drugs 0.000 description 1
• 229940091771 aspergillus fumigatus Drugs 0.000 description 1
• 201000009807 aspiration pneumonia Diseases 0.000 description 1
• 238000000889 atomisation Methods 0.000 description 1
• 229960000396 atropine Drugs 0.000 description 1
• RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
• 229960002028 atropine sulfate Drugs 0.000 description 1
• 230000002238 attenuated effect Effects 0.000 description 1
• 239000005667 attractant Substances 0.000 description 1
• 230000001363 autoimmune Effects 0.000 description 1
• 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
• 230000005784 autoimmunity Effects 0.000 description 1
• 229940065181 bacillus anthracis Drugs 0.000 description 1
• 235000015173 baked goods and baking mixes Nutrition 0.000 description 1
• 210000000270 basal cell Anatomy 0.000 description 1
• 210000002469 basement membrane Anatomy 0.000 description 1
• 235000013871 bee wax Nutrition 0.000 description 1
• 239000012166 beeswax Substances 0.000 description 1
• 230000003542 behavioural effect Effects 0.000 description 1
• 229960001192 bekanamycin Drugs 0.000 description 1
• UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
• 229960001950 benzethonium chloride Drugs 0.000 description 1
• 229960002903 benzyl benzoate Drugs 0.000 description 1
• 201000006486 beta-mannosidosis Diseases 0.000 description 1
• 235000013361 beverage Nutrition 0.000 description 1
• 229940069475 bile therapy drug Drugs 0.000 description 1
• 230000003115 biocidal effect Effects 0.000 description 1
• 238000006065 biodegradation reaction Methods 0.000 description 1
• 239000003124 biologic agent Substances 0.000 description 1
• 208000028683 bipolar I disease Diseases 0.000 description 1
• 238000004820 blood count Methods 0.000 description 1
• 230000036760 body temperature Effects 0.000 description 1
• 230000037396 body weight Effects 0.000 description 1
• 210000002798 bone marrow cell Anatomy 0.000 description 1
• 229940053031 botulinum toxin Drugs 0.000 description 1
• 108010006025 bovine growth hormone Proteins 0.000 description 1
• 201000006715 brachydactyly Diseases 0.000 description 1
• 235000008429 bread Nutrition 0.000 description 1
• 229940124630 bronchodilator Drugs 0.000 description 1
• 239000000168 bronchodilator agent Substances 0.000 description 1
• 229940056450 brucella abortus Drugs 0.000 description 1
• 229940038698 brucella melitensis Drugs 0.000 description 1
• 229940074375 burkholderia mallei Drugs 0.000 description 1
• 210000004899 c-terminal region Anatomy 0.000 description 1
• 229960001948 caffeine Drugs 0.000 description 1
• VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
• BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
• 229960004015 calcitonin Drugs 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 235000010410 calcium alginate Nutrition 0.000 description 1
• 239000000648 calcium alginate Substances 0.000 description 1
• 229960002681 calcium alginate Drugs 0.000 description 1
• 239000001110 calcium chloride Substances 0.000 description 1
• 229910001628 calcium chloride Inorganic materials 0.000 description 1
• FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
• 159000000007 calcium salts Chemical class 0.000 description 1
• CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
• 235000013539 calcium stearate Nutrition 0.000 description 1
• 239000008116 calcium stearate Substances 0.000 description 1
• 229940095731 candida albicans Drugs 0.000 description 1
• 229940041514 candida albicans extract Drugs 0.000 description 1
• 150000007942 carboxylates Chemical class 0.000 description 1
• 125000002843 carboxylic acid group Chemical group 0.000 description 1
• 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
• 108010041776 cardiotrophin 1 Proteins 0.000 description 1
• 239000002327 cardiovascular agent Substances 0.000 description 1
• 229940125692 cardiovascular agent Drugs 0.000 description 1
• 229960004203 carnitine Drugs 0.000 description 1
• NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 1
• 239000004359 castor oil Substances 0.000 description 1
• 235000019438 castor oil Nutrition 0.000 description 1
• 230000004098 cellular respiration Effects 0.000 description 1
• 210000003850 cellular structure Anatomy 0.000 description 1
• 235000010980 cellulose Nutrition 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 229940124587 cephalosporin Drugs 0.000 description 1
• 150000001780 cephalosporins Chemical class 0.000 description 1
• 235000013339 cereals Nutrition 0.000 description 1
• PBKVEOSEPXMKDN-LZHUFOCISA-N chembl2311030 Chemical compound CS(O)(=O)=O.CS(O)(=O)=O.CS(O)(=O)=O.CS(O)(=O)=O.C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)N4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)C(C)C)C(C)C)=C3C2=CNC3=C1.C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)N4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)C(C)CC)C(C)C)=C3C2=CNC3=C1.C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)N4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)CC(C)C)C(C)C)=C3C2=CNC3=C1.C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](C(N21)=O)(NC(=O)[C@H]1CN(C)[C@H]2[C@@H](C=3C=CC=C4NC=C(C=34)C2)C1)C(C)C)C1=CC=CC=C1 PBKVEOSEPXMKDN-LZHUFOCISA-N 0.000 description 1
• 229960004630 chlorambucil Drugs 0.000 description 1
• JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
• 229960004782 chlordiazepoxide Drugs 0.000 description 1
• ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 1
• 229960001616 chlormadinone acetate Drugs 0.000 description 1
• 229960004926 chlorobutanol Drugs 0.000 description 1
• ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
• 239000000812 cholinergic antagonist Substances 0.000 description 1
• 208000024971 chromosomal disease Diseases 0.000 description 1
• 210000001726 chromosome structure Anatomy 0.000 description 1
• 229960002376 chymotrypsin Drugs 0.000 description 1
• 208000016617 citrullinemia type I Diseases 0.000 description 1
• 206010009259 cleft lip Diseases 0.000 description 1
• 238000010367 cloning Methods 0.000 description 1
• 230000035602 clotting Effects 0.000 description 1
• QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 1
• 229960004170 clozapine Drugs 0.000 description 1
• AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
• 229940110456 cocoa butter Drugs 0.000 description 1
• 235000019868 cocoa butter Nutrition 0.000 description 1
• 239000003240 coconut oil Substances 0.000 description 1
• 235000019864 coconut oil Nutrition 0.000 description 1
• 229920001436 collagen Polymers 0.000 description 1
• 208000029742 colonic neoplasm Diseases 0.000 description 1
• 238000004040 coloring Methods 0.000 description 1
• 238000002648 combination therapy Methods 0.000 description 1
• 238000002485 combustion reaction Methods 0.000 description 1
• 230000000295 complement effect Effects 0.000 description 1
• 108010047295 complement receptors Proteins 0.000 description 1
• 102000006834 complement receptors Human genes 0.000 description 1
• 239000007891 compressed tablet Substances 0.000 description 1
• 239000007859 condensation product Substances 0.000 description 1
• ZHMWOVGZCINIHW-UHFFFAOYSA-N conduritol epoxide Chemical compound OC1C(O)C(O)C(O)C2OC21 ZHMWOVGZCINIHW-UHFFFAOYSA-N 0.000 description 1
• 235000009508 confectionery Nutrition 0.000 description 1
• 208000011664 congenital factor XI deficiency Diseases 0.000 description 1
• 238000010276 construction Methods 0.000 description 1
• 229940124558 contraceptive agent Drugs 0.000 description 1
• 238000010411 cooking Methods 0.000 description 1
• 235000014510 cooky Nutrition 0.000 description 1
• 239000008120 corn starch Substances 0.000 description 1
• 239000003218 coronary vasodilator agent Substances 0.000 description 1
• 239000002385 cottonseed oil Substances 0.000 description 1
• 235000012343 cottonseed oil Nutrition 0.000 description 1
• 235000012495 crackers Nutrition 0.000 description 1
• 201000003652 craniofrontonasal syndrome Diseases 0.000 description 1
• 201000003278 cryoglobulinemia Diseases 0.000 description 1
• 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
• 229960004397 cyclophosphamide Drugs 0.000 description 1
• 231100000433 cytotoxic Toxicity 0.000 description 1
• 230000001472 cytotoxic effect Effects 0.000 description 1
• 231100000895 deafness Toxicity 0.000 description 1
• 230000034994 death Effects 0.000 description 1
• 239000000850 decongestant Substances 0.000 description 1
• 229940124581 decongestants Drugs 0.000 description 1
• 230000007850 degeneration Effects 0.000 description 1
• 239000000412 dendrimer Substances 0.000 description 1
• 229920000736 dendritic polymer Polymers 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• 201000001981 dermatomyositis Diseases 0.000 description 1
• 108700001680 des-(1-3)- insulin-like growth factor 1 Proteins 0.000 description 1
• 229960001985 dextromethorphan Drugs 0.000 description 1
• XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 description 1
• 229960004193 dextropropoxyphene Drugs 0.000 description 1
• 201000007394 diastrophic dysplasia Diseases 0.000 description 1
• 229960003529 diazepam Drugs 0.000 description 1
• AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
• NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
• 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
• 235000019700 dicalcium phosphate Nutrition 0.000 description 1
• 229940038472 dicalcium phosphate Drugs 0.000 description 1
• 229960000452 diethylstilbestrol Drugs 0.000 description 1
• RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
• 239000003866 digestant Substances 0.000 description 1
• LIMAOLZSWRJOMG-HJPBWRTMSA-N dihydroergocristine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](C(N21)=O)(NC(=O)[C@H]1CN(C)[C@H]2[C@@H](C3=CC=CC4=NC=C([C]34)C2)C1)C(C)C)C1=CC=CC=C1 LIMAOLZSWRJOMG-HJPBWRTMSA-N 0.000 description 1
• 229960004318 dihydroergocristine Drugs 0.000 description 1
• UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
• MZDOIJOUFRQXHC-UHFFFAOYSA-N dimenhydrinate Chemical compound O=C1N(C)C(=O)N(C)C2=NC(Cl)=N[C]21.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 MZDOIJOUFRQXHC-UHFFFAOYSA-N 0.000 description 1
• 229960004993 dimenhydrinate Drugs 0.000 description 1
• 229950006690 dimethisterone Drugs 0.000 description 1
• 229960000520 diphenhydramine Drugs 0.000 description 1
• 208000037765 diseases and disorders Diseases 0.000 description 1
• 239000008298 dragée Substances 0.000 description 1
• 238000012377 drug delivery Methods 0.000 description 1
• 239000003596 drug target Substances 0.000 description 1
• 206010013932 dyslexia Diseases 0.000 description 1
• 208000002169 ectodermal dysplasia Diseases 0.000 description 1
• 208000031068 ectodermal dysplasia syndrome Diseases 0.000 description 1
• 239000003792 electrolyte Substances 0.000 description 1
• 238000010828 elution Methods 0.000 description 1
• 239000003974 emollient agent Substances 0.000 description 1
• 201000002491 encephalomyelitis Diseases 0.000 description 1
• 239000002702 enteric coating Substances 0.000 description 1
• 238000009505 enteric coating Methods 0.000 description 1
• 108700004025 env Genes Proteins 0.000 description 1
• 101150030339 env gene Proteins 0.000 description 1
• 230000007515 enzymatic degradation Effects 0.000 description 1
• 206010015037 epilepsy Diseases 0.000 description 1
• 229960003133 ergot alkaloid Drugs 0.000 description 1
• OFKDAAIKGIBASY-VFGNJEKYSA-N ergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C3=CC=CC4=NC=C([C]34)C2)=C1)C)C1=CC=CC=C1 OFKDAAIKGIBASY-VFGNJEKYSA-N 0.000 description 1
• 229960004943 ergotamine Drugs 0.000 description 1
• XCGSFFUVFURLIX-UHFFFAOYSA-N ergotaminine Natural products C1=C(C=2C=CC=C3NC=C(C=23)C2)C2N(C)CC1C(=O)NC(C(N12)=O)(C)OC1(O)C1CCCN1C(=O)C2CC1=CC=CC=C1 XCGSFFUVFURLIX-UHFFFAOYSA-N 0.000 description 1
• 239000003797 essential amino acid Substances 0.000 description 1
• 235000020776 essential amino acid Nutrition 0.000 description 1
• 201000006517 essential tremor Diseases 0.000 description 1
• 229960005309 estradiol Drugs 0.000 description 1
• 229960003399 estrone Drugs 0.000 description 1
• 229960002568 ethinylestradiol Drugs 0.000 description 1
• CHNXZKVNWQUJIB-CEGNMAFCSA-N ethisterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 CHNXZKVNWQUJIB-CEGNMAFCSA-N 0.000 description 1
• 229960000445 ethisterone Drugs 0.000 description 1
• 229940093499 ethyl acetate Drugs 0.000 description 1
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
• LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
• 229940093471 ethyl oleate Drugs 0.000 description 1
• 229940012028 ethynodiol diacetate Drugs 0.000 description 1
• ONKUMRGIYFNPJW-KIEAKMPYSA-N ethynodiol diacetate Chemical compound C1C[C@]2(C)[C@@](C#C)(OC(C)=O)CC[C@H]2[C@@H]2CCC3=C[C@@H](OC(=O)C)CC[C@@H]3[C@H]21 ONKUMRGIYFNPJW-KIEAKMPYSA-N 0.000 description 1
• 210000003527 eukaryotic cell Anatomy 0.000 description 1
• 238000011156 evaluation Methods 0.000 description 1
• 230000005284 excitation Effects 0.000 description 1
• 210000001723 extracellular space Anatomy 0.000 description 1
• 208000012043 faciodigitogenital syndrome Diseases 0.000 description 1
• 208000005376 factor X deficiency Diseases 0.000 description 1
• 208000027826 familial dysfibrinogenemia Diseases 0.000 description 1
• 201000011110 familial lipoprotein lipase deficiency Diseases 0.000 description 1
• 230000004129 fatty acid metabolism Effects 0.000 description 1
• 239000012091 fetal bovine serum Substances 0.000 description 1
• 229940126864 fibroblast growth factor Drugs 0.000 description 1
• 235000019688 fish Nutrition 0.000 description 1
• 239000000834 fixative Substances 0.000 description 1
• 238000000684 flow cytometry Methods 0.000 description 1
• 229940028334 follicle stimulating hormone Drugs 0.000 description 1
• 230000037406 food intake Effects 0.000 description 1
• 235000011194 food seasoning agent Nutrition 0.000 description 1
• 229940118764 francisella tularensis Drugs 0.000 description 1
• 235000012055 fruits and vegetables Nutrition 0.000 description 1
• 244000053095 fungal pathogen Species 0.000 description 1
• UPBDXRPQPOWRKR-UHFFFAOYSA-N furan-2,5-dione;methoxyethene Chemical compound COC=C.O=C1OC(=O)C=C1 UPBDXRPQPOWRKR-UHFFFAOYSA-N 0.000 description 1
• 201000007412 galactokinase deficiency Diseases 0.000 description 1
• 229930182830 galactose Natural products 0.000 description 1
• 208000011836 galactose epimerase deficiency Diseases 0.000 description 1
• 229940044627 gamma-interferon Drugs 0.000 description 1
• 229920000370 gamma-poly(glutamate) polymer Polymers 0.000 description 1
• 230000002496 gastric effect Effects 0.000 description 1
• 210000005095 gastrointestinal system Anatomy 0.000 description 1
• 238000001476 gene delivery Methods 0.000 description 1
• 238000010363 gene targeting Methods 0.000 description 1
• 108091006104 gene-regulatory proteins Proteins 0.000 description 1
• 102000034356 gene-regulatory proteins Human genes 0.000 description 1
• 238000007429 general method Methods 0.000 description 1
• 238000010448 genetic screening Methods 0.000 description 1
• 229960002518 gentamicin Drugs 0.000 description 1
• MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
• 229960004666 glucagon Drugs 0.000 description 1
• 229940046240 glucomannan Drugs 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 208000005594 glucose-galactose malabsorption Diseases 0.000 description 1
• 208000015362 glutaric aciduria Diseases 0.000 description 1
• YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
• 201000003702 glycerol kinase deficiency Diseases 0.000 description 1
• SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
• ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
• 229940074045 glyceryl distearate Drugs 0.000 description 1
• 229940075507 glyceryl monostearate Drugs 0.000 description 1
• 229960003711 glyceryl trinitrate Drugs 0.000 description 1
• 208000007345 glycogen storage disease Diseases 0.000 description 1
• 201000004541 glycogen storage disease I Diseases 0.000 description 1
• 201000004534 glycogen storage disease V Diseases 0.000 description 1
• 201000004510 glycogen storage disease VI Diseases 0.000 description 1
• 201000009339 glycogen storage disease VII Diseases 0.000 description 1
• 229930182470 glycoside Natural products 0.000 description 1
• 150000002338 glycosides Chemical class 0.000 description 1
• 150000002339 glycosphingolipids Chemical class 0.000 description 1
• 239000002622 gonadotropin Substances 0.000 description 1
• 210000004884 grey matter Anatomy 0.000 description 1
• 235000010417 guar gum Nutrition 0.000 description 1
• 239000000665 guar gum Substances 0.000 description 1
• 229960002154 guar gum Drugs 0.000 description 1
• 229940047650 haemophilus influenzae Drugs 0.000 description 1
• 230000003676 hair loss Effects 0.000 description 1
• 238000003306 harvesting Methods 0.000 description 1
• 208000016354 hearing loss disease Diseases 0.000 description 1
• 208000019622 heart disease Diseases 0.000 description 1
• 238000010438 heat treatment Methods 0.000 description 1
• 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
• 239000003219 hemolytic agent Substances 0.000 description 1
• 229960002897 heparin Drugs 0.000 description 1
• 229920000669 heparin Polymers 0.000 description 1
• 206010019847 hepatosplenomegaly Diseases 0.000 description 1
• 208000033666 hereditary antithrombin deficiency Diseases 0.000 description 1
• 208000007000 hereditary hyperbilirubinemia Diseases 0.000 description 1
• 208000003215 hereditary nephritis Diseases 0.000 description 1
• 208000013746 hereditary thrombophilia due to congenital protein C deficiency Diseases 0.000 description 1
• 239000000833 heterodimer Substances 0.000 description 1
• 208000006599 histidinemia Diseases 0.000 description 1
• 229920001519 homopolymer Polymers 0.000 description 1
• 229940088597 hormone Drugs 0.000 description 1
• 239000005556 hormone Substances 0.000 description 1
• 102000044954 human KRT14 Human genes 0.000 description 1
• 239000003906 humectant Substances 0.000 description 1
• 229960002773 hyaluronidase Drugs 0.000 description 1
• 229960000890 hydrocortisone Drugs 0.000 description 1
• XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
• 230000003301 hydrolyzing effect Effects 0.000 description 1
• XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
• WYKNNRXUNHJPDJ-UHFFFAOYSA-N hydroxy-[(trimethylazaniumyl)methyl]phosphinate Chemical compound C[N+](C)(C)CP(O)([O-])=O WYKNNRXUNHJPDJ-UHFFFAOYSA-N 0.000 description 1
• WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
• 229940124512 hyoscine hydrobromide Drugs 0.000 description 1
• 206010066130 hyper-IgM syndrome Diseases 0.000 description 1
• 208000036796 hyperbilirubinemia Diseases 0.000 description 1
• 208000034192 hyperlysinemia Diseases 0.000 description 1
• 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
• 230000001900 immune effect Effects 0.000 description 1
• 230000008073 immune recognition Effects 0.000 description 1
• 238000003125 immunofluorescent labeling Methods 0.000 description 1
• 229940072221 immunoglobulins Drugs 0.000 description 1
• 239000002955 immunomodulating agent Substances 0.000 description 1
• 230000002584 immunomodulator Effects 0.000 description 1
• 229940121354 immunomodulator Drugs 0.000 description 1
• 230000001024 immunotherapeutic effect Effects 0.000 description 1
• 230000002637 immunotoxin Effects 0.000 description 1
• 239000002596 immunotoxin Substances 0.000 description 1
• 231100000608 immunotoxin Toxicity 0.000 description 1
• 229940051026 immunotoxin Drugs 0.000 description 1
• 238000002513 implantation Methods 0.000 description 1
• 230000006872 improvement Effects 0.000 description 1
• 208000026203 inborn glycerol kinase deficiency Diseases 0.000 description 1
• 229960000905 indomethacin Drugs 0.000 description 1
• 230000006698 induction Effects 0.000 description 1
• 230000001939 inductive effect Effects 0.000 description 1
• 230000002458 infectious effect Effects 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 208000015978 inherited metabolic disease Diseases 0.000 description 1
• 239000000893 inhibin Substances 0.000 description 1
• ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
• 230000015788 innate immune response Effects 0.000 description 1
• 239000002054 inoculum Substances 0.000 description 1
• 238000003780 insertion Methods 0.000 description 1
• 230000037431 insertion Effects 0.000 description 1
• 108091022911 insulin-like growth factor binding Proteins 0.000 description 1
• 102000028416 insulin-like growth factor binding Human genes 0.000 description 1
• 108010044426 integrins Proteins 0.000 description 1
• 102000006495 integrins Human genes 0.000 description 1
• 108700027921 interferon tau Proteins 0.000 description 1
• 229940076144 interleukin-10 Drugs 0.000 description 1
• 229940074383 interleukin-11 Drugs 0.000 description 1
• 229940117681 interleukin-12 Drugs 0.000 description 1
• 229940076264 interleukin-3 Drugs 0.000 description 1
• 229940028885 interleukin-4 Drugs 0.000 description 1
• 229940100602 interleukin-5 Drugs 0.000 description 1
• 229940100601 interleukin-6 Drugs 0.000 description 1
• 229940100994 interleukin-7 Drugs 0.000 description 1
• 229940118526 interleukin-9 Drugs 0.000 description 1
• 210000004347 intestinal mucosa Anatomy 0.000 description 1
• 238000010255 intramuscular injection Methods 0.000 description 1
• 239000007927 intramuscular injection Substances 0.000 description 1
• 238000010253 intravenous injection Methods 0.000 description 1
• 239000003456 ion exchange resin Substances 0.000 description 1
• 229920003303 ion-exchange polymer Polymers 0.000 description 1
• 208000019975 isolated glycerol kinase deficiency Diseases 0.000 description 1
• 208000013049 isolated hemihyperplasia Diseases 0.000 description 1
• 239000007951 isotonicity adjuster Substances 0.000 description 1
• 230000000366 juvenile effect Effects 0.000 description 1
• 208000017476 juvenile neuronal ceroid lipofuscinosis Diseases 0.000 description 1
• 229960000318 kanamycin Drugs 0.000 description 1
• SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
• 229930182823 kanamycin A Natural products 0.000 description 1
• SKKLOUVUUNMCJE-FQSMHNGLSA-N kanamycin B Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SKKLOUVUUNMCJE-FQSMHNGLSA-N 0.000 description 1
• 229930182824 kanamycin B Natural products 0.000 description 1
• 238000011813 knockout mouse model Methods 0.000 description 1
• 210000002429 large intestine Anatomy 0.000 description 1
• 201000010901 lateral sclerosis Diseases 0.000 description 1
• 231100000518 lethal Toxicity 0.000 description 1
• 230000001665 lethal effect Effects 0.000 description 1
• 210000000265 leukocyte Anatomy 0.000 description 1
• 235000019421 lipase Nutrition 0.000 description 1
• 238000001638 lipofection Methods 0.000 description 1
• 230000008604 lipoprotein metabolism Effects 0.000 description 1
• 239000004973 liquid crystal related substance Substances 0.000 description 1
• 239000012669 liquid formulation Substances 0.000 description 1
• 210000005228 liver tissue Anatomy 0.000 description 1
• 235000011475 lollipops Nutrition 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 239000007937 lozenge Substances 0.000 description 1
• 201000005202 lung cancer Diseases 0.000 description 1
• 208000020816 lung neoplasm Diseases 0.000 description 1
• 239000003580 lung surfactant Substances 0.000 description 1
• 229940066294 lung surfactant Drugs 0.000 description 1
• 206010025135 lupus erythematosus Diseases 0.000 description 1
• 229940040129 luteinizing hormone Drugs 0.000 description 1
• 210000005004 lymphoid follicle Anatomy 0.000 description 1
• 229960001910 lynestrenol Drugs 0.000 description 1
• 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
• 235000010335 lysozyme Nutrition 0.000 description 1
• ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
• 239000001095 magnesium carbonate Substances 0.000 description 1
• 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• 239000011976 maleic acid Substances 0.000 description 1
• FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 229960000299 mazindol Drugs 0.000 description 1
• 230000010534 mechanism of action Effects 0.000 description 1
• 229960004961 mechlorethamine Drugs 0.000 description 1
• HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
• 229960002985 medroxyprogesterone acetate Drugs 0.000 description 1
• PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 1
• 229960004296 megestrol acetate Drugs 0.000 description 1
• RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
• 201000001441 melanoma Diseases 0.000 description 1
• 229960004805 melengestrol Drugs 0.000 description 1
• OKHAOBQKCCIRLO-IBVJIVQJSA-N melengestrol Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC(=C)[C@@](C(=O)C)(O)[C@@]1(C)CC2 OKHAOBQKCCIRLO-IBVJIVQJSA-N 0.000 description 1
• 229960001924 melphalan Drugs 0.000 description 1
• SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
• 229960000906 mephenytoin Drugs 0.000 description 1
• GMHKMTDVRCWUDX-UHFFFAOYSA-N mephenytoin Chemical compound C=1C=CC=CC=1C1(CC)NC(=O)N(C)C1=O GMHKMTDVRCWUDX-UHFFFAOYSA-N 0.000 description 1
• 229960004815 meprobamate Drugs 0.000 description 1
• SLVMESMUVMCQIY-UHFFFAOYSA-N mesoridazine Chemical compound CN1CCCCC1CCN1C2=CC(S(C)=O)=CC=C2SC2=CC=CC=C21 SLVMESMUVMCQIY-UHFFFAOYSA-N 0.000 description 1
• 229960000300 mesoridazine Drugs 0.000 description 1
• 229960001390 mestranol Drugs 0.000 description 1
• IMSSROKUHAOUJS-MJCUULBUSA-N mestranol Chemical compound C1C[C@]2(C)[C@@](C#C)(O)CC[C@H]2[C@@H]2CCC3=CC(OC)=CC=C3[C@H]21 IMSSROKUHAOUJS-MJCUULBUSA-N 0.000 description 1
• 208000030159 metabolic disease Diseases 0.000 description 1
• 230000004148 metal metabolism Effects 0.000 description 1
• 229960000485 methotrexate Drugs 0.000 description 1
• LZCOQTDXKCNBEE-IKIFYQGPSA-N methscopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)C)=CC=CC=C1 LZCOQTDXKCNBEE-IKIFYQGPSA-N 0.000 description 1
• 229920000609 methyl cellulose Polymers 0.000 description 1
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
• 239000001923 methylcellulose Substances 0.000 description 1
• 235000010981 methylcellulose Nutrition 0.000 description 1
• 201000003694 methylmalonic acidemia Diseases 0.000 description 1
• LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
• 229960001383 methylscopolamine Drugs 0.000 description 1
• 229950002918 metiapine Drugs 0.000 description 1
• 229960000282 metronidazole Drugs 0.000 description 1
• VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
• 230000003641 microbiacidal effect Effects 0.000 description 1
• 239000002480 mineral oil Substances 0.000 description 1
• 239000006151 minimal media Substances 0.000 description 1
• 208000015994 miscarriage Diseases 0.000 description 1
• 239000007932 molded tablet Substances 0.000 description 1
• 239000003068 molecular probe Substances 0.000 description 1
• CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
• 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
• 229960005181 morphine Drugs 0.000 description 1
• 208000005264 motor neuron disease Diseases 0.000 description 1
• 201000007769 mucolipidosis Diseases 0.000 description 1
• 208000020460 mucolipidosis II alpha/beta Diseases 0.000 description 1
• 208000020468 mucolipidosis III alpha/beta Diseases 0.000 description 1
• 201000002273 mucopolysaccharidosis II Diseases 0.000 description 1
• 208000005340 mucopolysaccharidosis III Diseases 0.000 description 1
• 208000000690 mucopolysaccharidosis VI Diseases 0.000 description 1
• 201000009671 multidrug-resistant tuberculosis Diseases 0.000 description 1
• 208000028261 multifactorial inheritance Diseases 0.000 description 1
• 206010051747 multiple endocrine neoplasia Diseases 0.000 description 1
• 229940051921 muramidase Drugs 0.000 description 1
• 230000004220 muscle function Effects 0.000 description 1
• 206010028417 myasthenia gravis Diseases 0.000 description 1
• 230000001016 myotrophic effect Effects 0.000 description 1
• PLPRGLOFPNJOTN-UHFFFAOYSA-N narcotine Natural products COc1ccc2C(OC(=O)c2c1OC)C3Cc4c(CN3C)cc5OCOc5c4OC PLPRGLOFPNJOTN-UHFFFAOYSA-N 0.000 description 1
• 210000000822 natural killer cell Anatomy 0.000 description 1
• 238000002663 nebulization Methods 0.000 description 1
• 229960004927 neomycin Drugs 0.000 description 1
• 229940053128 nerve growth factor Drugs 0.000 description 1
• 210000000653 nervous system Anatomy 0.000 description 1
• 201000004931 neurofibromatosis Diseases 0.000 description 1
• 239000003176 neuroleptic agent Substances 0.000 description 1
• 201000007607 neuronal ceroid lipofuscinosis 3 Diseases 0.000 description 1
• 229940032018 neurotrophin 3 Drugs 0.000 description 1
• 230000003472 neutralizing effect Effects 0.000 description 1
• 201000005734 nevoid basal cell carcinoma syndrome Diseases 0.000 description 1
• 231100000344 non-irritating Toxicity 0.000 description 1
• 239000012457 nonaqueous media Substances 0.000 description 1
• 231100000252 nontoxic Toxicity 0.000 description 1
• 230000003000 nontoxic effect Effects 0.000 description 1
• 239000000346 nonvolatile oil Substances 0.000 description 1
• 229960001858 norethynodrel Drugs 0.000 description 1
• 229960000417 norgestimate Drugs 0.000 description 1
• KIQQMECNKUGGKA-NMYWJIRASA-N norgestimate Chemical compound O/N=C/1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(OC(C)=O)C#C)[C@@H]4[C@@H]3CCC2=C\1 KIQQMECNKUGGKA-NMYWJIRASA-N 0.000 description 1
• 229960004708 noscapine Drugs 0.000 description 1
• 230000037360 nucleotide metabolism Effects 0.000 description 1
• 210000004287 null lymphocyte Anatomy 0.000 description 1
• 239000002417 nutraceutical Substances 0.000 description 1
• 235000021436 nutraceutical agent Nutrition 0.000 description 1
• 235000015097 nutrients Nutrition 0.000 description 1
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
• 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
• 238000002515 oligonucleotide synthesis Methods 0.000 description 1
• 210000003463 organelle Anatomy 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 150000002895 organic esters Chemical class 0.000 description 1
• 229940082615 organic nitrates used in cardiac disease Drugs 0.000 description 1
• 201000010464 osteogenesis imperfecta type 1 Diseases 0.000 description 1
• 230000002138 osteoinductive effect Effects 0.000 description 1
• 229960000625 oxytetracycline Drugs 0.000 description 1
• IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
• 235000019366 oxytetracycline Nutrition 0.000 description 1
• 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
• 238000012858 packaging process Methods 0.000 description 1
• 230000000242 pagocytic effect Effects 0.000 description 1
• 210000002741 palatine tonsil Anatomy 0.000 description 1
• 201000002528 pancreatic cancer Diseases 0.000 description 1
• 208000008443 pancreatic carcinoma Diseases 0.000 description 1
• 229960005489 paracetamol Drugs 0.000 description 1
• 229920002866 paraformaldehyde Polymers 0.000 description 1
• 239000000734 parasympathomimetic agent Substances 0.000 description 1
• 239000000199 parathyroid hormone Substances 0.000 description 1
• 229960001319 parathyroid hormone Drugs 0.000 description 1
• 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 description 1
• 230000008506 pathogenesis Effects 0.000 description 1
• 230000007170 pathology Effects 0.000 description 1
• 102000013234 pattern recognition receptor activity proteins Human genes 0.000 description 1
• 230000000149 penetrating effect Effects 0.000 description 1
• 229940056360 penicillin g Drugs 0.000 description 1
• 150000002960 penicillins Chemical class 0.000 description 1
• 229960001412 pentobarbital Drugs 0.000 description 1
• 239000002304 perfume Substances 0.000 description 1
• 210000002824 peroxisome Anatomy 0.000 description 1
• 229960000762 perphenazine Drugs 0.000 description 1
• 229960000482 pethidine Drugs 0.000 description 1
• 210000000680 phagosome Anatomy 0.000 description 1
• DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
• 229960002695 phenobarbital Drugs 0.000 description 1
• WRLGYAWRGXKSKG-UHFFFAOYSA-M phenobarbital sodium Chemical compound [Na+].C=1C=CC=CC=1C1(CC)C(=O)NC([O-])=NC1=O WRLGYAWRGXKSKG-UHFFFAOYSA-M 0.000 description 1
• 229960003742 phenol Drugs 0.000 description 1
• 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
• 229960003562 phentermine Drugs 0.000 description 1
• WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
• 229960002895 phenylbutazone Drugs 0.000 description 1
• VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
• HKOOXMFOFWEVGF-UHFFFAOYSA-N phenylhydrazine Chemical compound NNC1=CC=CC=C1 HKOOXMFOFWEVGF-UHFFFAOYSA-N 0.000 description 1
• 229940067157 phenylhydrazine Drugs 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 230000000704 physical effect Effects 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• 239000003123 plant toxin Substances 0.000 description 1
• 229940127126 plasminogen activator Drugs 0.000 description 1
• 231100000614 poison Toxicity 0.000 description 1
• 229920001432 poly(L-lactide) Polymers 0.000 description 1
• 229920001308 poly(aminoacid) Polymers 0.000 description 1
• 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
• 239000002745 poly(ortho ester) Substances 0.000 description 1
• 229920002627 poly(phosphazenes) Polymers 0.000 description 1
• 229920000333 poly(propyleneimine) Polymers 0.000 description 1
• 229920000172 poly(styrenesulfonic acid) Polymers 0.000 description 1
• 108010064470 polyaspartate Proteins 0.000 description 1
• 208000030761 polycystic kidney disease Diseases 0.000 description 1
• 230000003234 polygenic effect Effects 0.000 description 1
• 208000005987 polymyositis Diseases 0.000 description 1
• 229920005862 polyol Polymers 0.000 description 1
• 150000003077 polyols Chemical class 0.000 description 1
• 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
• 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
• 229920000053 polysorbate 80 Polymers 0.000 description 1
• 229920002223 polystyrene Polymers 0.000 description 1
• 239000001103 potassium chloride Substances 0.000 description 1
• 235000011164 potassium chloride Nutrition 0.000 description 1
• 229920001592 potato starch Polymers 0.000 description 1
• 238000001556 precipitation Methods 0.000 description 1
• 229960005205 prednisolone Drugs 0.000 description 1
• OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
• 229960004618 prednisone Drugs 0.000 description 1
• XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
• 208000001000 prekallikrein deficiency Diseases 0.000 description 1
• 238000003825 pressing Methods 0.000 description 1
• 230000002265 prevention Effects 0.000 description 1
• 235000020991 processed meat Nutrition 0.000 description 1
• 238000012545 processing Methods 0.000 description 1
• 239000000583 progesterone congener Substances 0.000 description 1
• 229940097325 prolactin Drugs 0.000 description 1
• 150000003147 proline derivatives Chemical class 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical class CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
• 108010087851 prorelaxin Proteins 0.000 description 1
• 150000003180 prostaglandins Chemical class 0.000 description 1
• 230000012846 protein folding Effects 0.000 description 1
• 208000033685 pterin-4 alpha-carbinolamine dehydratase 1 deficiency Diseases 0.000 description 1
• 238000000746 purification Methods 0.000 description 1
• 229960000611 pyrimethamine Drugs 0.000 description 1
• WKSAUQYGYAYLPV-UHFFFAOYSA-N pyrimethamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1 WKSAUQYGYAYLPV-UHFFFAOYSA-N 0.000 description 1
• 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
• 125000001453 quaternary ammonium group Chemical group 0.000 description 1
• 238000010791 quenching Methods 0.000 description 1
• 229940080360 rauwolfia alkaloid Drugs 0.000 description 1
• 208000002574 reactive arthritis Diseases 0.000 description 1
• 238000010188 recombinant method Methods 0.000 description 1
• 230000006798 recombination Effects 0.000 description 1
• 210000000664 rectum Anatomy 0.000 description 1
• 230000001105 regulatory effect Effects 0.000 description 1
• 229960003147 reserpine Drugs 0.000 description 1
• BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
• 230000004044 response Effects 0.000 description 1
• 230000028527 righting reflex Effects 0.000 description 1
• 238000012502 risk assessment Methods 0.000 description 1
• MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
• 230000004434 saccadic eye movement Effects 0.000 description 1
• 108010038196 saccharide-binding proteins Proteins 0.000 description 1
• CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
• 229940081974 saccharin Drugs 0.000 description 1
• 235000019204 saccharin Nutrition 0.000 description 1
• 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
• 229940085605 saccharin sodium Drugs 0.000 description 1
• 150000003902 salicylic acid esters Chemical class 0.000 description 1
• 239000000523 sample Substances 0.000 description 1
• 238000005070 sampling Methods 0.000 description 1
• 201000000306 sarcoidosis Diseases 0.000 description 1
• 201000000980 schizophrenia Diseases 0.000 description 1
• LACQPOBCQQPVIT-SEYKEWMNSA-N scopolamine hydrobromide trihydrate Chemical compound O.O.O.Br.C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 LACQPOBCQQPVIT-SEYKEWMNSA-N 0.000 description 1
• KQPKPCNLIDLUMF-UHFFFAOYSA-N secobarbital Chemical compound CCCC(C)C1(CC=C)C(=O)NC(=O)NC1=O KQPKPCNLIDLUMF-UHFFFAOYSA-N 0.000 description 1
• 230000004799 sedative–hypnotic effect Effects 0.000 description 1
• 238000012163 sequencing technique Methods 0.000 description 1
• 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
• 230000020509 sex determination Effects 0.000 description 1
• 229940007046 shigella dysenteriae Drugs 0.000 description 1
• 150000004760 silicates Chemical class 0.000 description 1
• RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
• 239000000377 silicon dioxide Substances 0.000 description 1
• 235000012239 silicon dioxide Nutrition 0.000 description 1
• 235000012177 snack cakes Nutrition 0.000 description 1
• 239000003998 snake venom Substances 0.000 description 1
• 235000010413 sodium alginate Nutrition 0.000 description 1
• 239000000661 sodium alginate Substances 0.000 description 1
• 229940005550 sodium alginate Drugs 0.000 description 1
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
• 239000001509 sodium citrate Substances 0.000 description 1
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
• 239000001488 sodium phosphate Substances 0.000 description 1
• 229910000162 sodium phosphate Inorganic materials 0.000 description 1
• 239000012064 sodium phosphate buffer Substances 0.000 description 1
• 235000011008 sodium phosphates Nutrition 0.000 description 1
• 229940079832 sodium starch glycolate Drugs 0.000 description 1
• 239000008109 sodium starch glycolate Substances 0.000 description 1
• 229920003109 sodium starch glycolate Polymers 0.000 description 1
• 239000007901 soft capsule Substances 0.000 description 1
• 239000008247 solid mixture Substances 0.000 description 1
• 238000000527 sonication Methods 0.000 description 1
• 238000001228 spectrum Methods 0.000 description 1
• 230000001150 spermicidal effect Effects 0.000 description 1
• 229940063675 spermine Drugs 0.000 description 1
• 239000012798 spherical particle Substances 0.000 description 1
• 235000013599 spices Nutrition 0.000 description 1
• 208000002320 spinal muscular atrophy Diseases 0.000 description 1
• 210000001655 splenic red pulp macrophage Anatomy 0.000 description 1
• 208000000995 spontaneous abortion Diseases 0.000 description 1
• 239000003381 stabilizer Substances 0.000 description 1
• 230000000087 stabilizing effect Effects 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 229940032147 starch Drugs 0.000 description 1
• 230000024188 startle response Effects 0.000 description 1
• 239000008117 stearic acid Substances 0.000 description 1
• 150000003431 steroids Chemical class 0.000 description 1
• 239000011232 storage material Substances 0.000 description 1
• 229960005322 streptomycin Drugs 0.000 description 1
• 239000001384 succinic acid Substances 0.000 description 1
• 229940124530 sulfonamide Drugs 0.000 description 1
• 150000003456 sulfonamides Chemical class 0.000 description 1
• BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
• 230000004083 survival effect Effects 0.000 description 1
• 230000008961 swelling Effects 0.000 description 1
• 230000009182 swimming Effects 0.000 description 1
• 229940127230 sympathomimetic drug Drugs 0.000 description 1
• 229920001059 synthetic polymer Polymers 0.000 description 1
• 229960003188 temazepam Drugs 0.000 description 1
• IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 1
• IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 description 1
• 238000012360 testing method Methods 0.000 description 1
• 229960003604 testosterone Drugs 0.000 description 1
• 229960001712 testosterone propionate Drugs 0.000 description 1
• 229940040944 tetracyclines Drugs 0.000 description 1
• 238000002560 therapeutic procedure Methods 0.000 description 1
• 239000002562 thickening agent Substances 0.000 description 1
• XCTYLCDETUVOIP-UHFFFAOYSA-N thiethylperazine Chemical compound C12=CC(SCC)=CC=C2SC2=CC=CC=C2N1CCCN1CCN(C)CC1 XCTYLCDETUVOIP-UHFFFAOYSA-N 0.000 description 1
• 229960004869 thiethylperazine Drugs 0.000 description 1
• 229960002784 thioridazine Drugs 0.000 description 1
• 229960001196 thiotepa Drugs 0.000 description 1
• 229960004072 thrombin Drugs 0.000 description 1
• 206010043554 thrombocytopenia Diseases 0.000 description 1
• 201000007420 thrombocytopenia-absent radius syndrome Diseases 0.000 description 1
• 201000005665 thrombophilia Diseases 0.000 description 1
• 241001147422 tick-borne encephalitis virus group Species 0.000 description 1
• 239000003104 tissue culture media Substances 0.000 description 1
• 238000004448 titration Methods 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• 239000003440 toxic substance Substances 0.000 description 1
• 239000003204 tranquilizing agent Substances 0.000 description 1
• 230000002936 tranquilizing effect Effects 0.000 description 1
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
• 230000009466 transformation Effects 0.000 description 1
• 230000014621 translational initiation Effects 0.000 description 1
• 238000011269 treatment regimen Methods 0.000 description 1
• 150000003626 triacylglycerols Chemical class 0.000 description 1
• IRYJRGCIQBGHIV-UHFFFAOYSA-N trimethadione Chemical compound CN1C(=O)OC(C)(C)C1=O IRYJRGCIQBGHIV-UHFFFAOYSA-N 0.000 description 1
• 229960004453 trimethadione Drugs 0.000 description 1
• SZYJELPVAFJOGJ-UHFFFAOYSA-N trimethylamine hydrochloride Chemical compound Cl.CN(C)C SZYJELPVAFJOGJ-UHFFFAOYSA-N 0.000 description 1
• 229960003223 tripelennamine Drugs 0.000 description 1
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
• RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
• 239000002753 trypsin inhibitor Substances 0.000 description 1
• 239000012137 tryptone Substances 0.000 description 1
• 201000008827 tuberculosis Diseases 0.000 description 1
• 208000009999 tuberous sclerosis Diseases 0.000 description 1
• 210000004881 tumor cell Anatomy 0.000 description 1
• 201000007972 tyrosinemia type I Diseases 0.000 description 1
• 241001529453 unidentified herpesvirus Species 0.000 description 1
• 208000030954 urea cycle disease Diseases 0.000 description 1
• VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
• 229960005356 urokinase Drugs 0.000 description 1
• 210000003934 vacuole Anatomy 0.000 description 1
• 201000006266 variola major Diseases 0.000 description 1
• 201000000866 velocardiofacial syndrome Diseases 0.000 description 1
• 229920002554 vinyl polymer Polymers 0.000 description 1
• 239000013603 viral vector Substances 0.000 description 1
• 229940088594 vitamin Drugs 0.000 description 1
• 239000011782 vitamin Substances 0.000 description 1
• 235000013343 vitamin Nutrition 0.000 description 1
• 229930003231 vitamin Natural products 0.000 description 1
• 201000007790 vitelliform macular dystrophy Diseases 0.000 description 1
• 208000020938 vitelliform macular dystrophy 2 Diseases 0.000 description 1
• 239000000341 volatile oil Substances 0.000 description 1
• 208000006542 von Hippel-Lindau disease Diseases 0.000 description 1
• 238000009736 wetting Methods 0.000 description 1
• NLIVDORGVGAOOJ-MAHBNPEESA-M xylene cyanol Chemical compound [Na+].C1=C(C)C(NCC)=CC=C1C(\C=1C(=CC(OS([O-])=O)=CC=1)OS([O-])=O)=C\1C=C(C)\C(=[NH+]/CC)\C=C/1 NLIVDORGVGAOOJ-MAHBNPEESA-M 0.000 description 1
• 239000012138 yeast extract Substances 0.000 description 1